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ABSTRACT 
THERAPEUTIC APPLICATIONS AND SPECIFICITY OF ACTION OF 
DESIGNER NUCLEASES FOR PRECISION GENOME ENGINEERING 
Chukwuka A. Didigu 
Robert W. Doms 
Designer nucleases allow for the precise modification of a given DNA sequence 
by the introduction of a sequence-specific double strand break. This targeted 
genetic engineering confers the ability to modify genomes of complex organisms, 
and has far-reaching applications in human medicine, agriculture, and 
biotechnology. As these nucleases act in a sequence specific manner, 
understanding their specificity is of paramount importance to prevent potentially 
genotoxic side effects. In this thesis, I assessed the ability of a class of designer 
nucleases (ZFNs)—zinc finger nucleases—to simultaneously inactivate two 
genes encoding entry factors required for HIV infection in human CD4 T cells. 
Additionally, I sought to develop a high-throughput means of identifying sites of 
designer nuclease off-target activity across the genome, in an effort to better 
understand the factors governing designer nuclease specificity. This work 
demonstrates the ability of ZFNs to simultaneously modify two distinct genetic 
loci in primary human CD4 T cells—the main target of HIV infection. These gene-
modified cells are protected from HIV infection and represent a novel means of 
treating—and potentially curing HIV infection. This work also demonstrates that 
DNA double-strand breaks introduced by a single designer nuclease at on- and 
off-target loci can result in the formation of genomic rearrangements. Taken 
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together, this work advances in the field of genome engineering on two fronts—a 
novel therapeutic application of designer nucleases and a novel means of 
detecting off-target genomic modification. 
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Chapter 1. Designer nucleases are a flexible tool for precision genome 
engineering 
I. Genome engineering using designer nucleases 
The ability to introduce stable, heritable, genetic modifications in complex 
organisms provides a unique opportunity to alter such organisms for therapeutic, 
biotechnology and research purposes. This process of genome engineering can 
be achieved using a diverse family of molecules called designer nucleases. 
Designer nucleases are chimeric molecules that can be engineered to bind a 
given DNA sequence and once bound to their target, introduce a double-strand 
break (DSB). This DSB serves as the nexus for a number of genomic alterations 
including inactivation of target genes, gene correction, and the insertion of new 
coding sequences (reviewed in (1)). Inactivation of a target gene requires DSB 
repair to occur via the error-prone cellular non-homologous end-joining (NHEJ) 
pathway, which most often generates random insertions and deletions that result 
in a non-functional gene product (2). Conversely, the presence of a DNA 
template with homology to the region surrounding the DSB—such as a sister 
chromatid—allows for DSB repair to occur via the higher fidelity homologous 
repair pathway. As such, the concomitant introduction of a DSB by a designer 
nuclease and delivery of a custom DNA template with homology to the site of the 
DSB allows for the introduction of an investigator-designed DNA sequence into a 
given locus. These sequences can range from single base pair substitutions to 
the insertion of large segments of coding DNA. To date, the three most widely 
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used designer nucleases include Zinc Finger Nucleases (ZFNs), Transcription 
Activator-Like Effector Nucleases (TALENs) and Clustered Regularly 
Interspaced Short Palindromic Repeat-associated nucleases (the CRISPR/Cas 
system). 
II. Zinc Finger Nucleases 
 ZFNs consist of a DNA-binding Cys2-His2 zinc finger protein (ZFP) fused 
to the nuclease domain of the dimeric FokI restriction endonuclease (3-5). The 
Cys2-His2 zinc finger domain is one of the most common DNA binding motifs 
found in eukaryotic transcription factors. These domains have a ββα-fold 
conformation, and amino acids in the α-helix of the zinc finger contact 3-4 base 
pairs in the major groove of DNA. The ability to target longer sequences was 
made possible by the development a polypeptide linker that allows for the 
generation of tandem arrays of zinc fingers, and has resulted in enhanced ZFN 
specificity (6). To date, ZFPs that bind most of the 64 possible DNA triplets have 
been designed, greatly aiding the synthesis of ZFNs that target sequences long 
enough to ensure genome-wide specificity.  
ZFNs function as a pair, and to introduce a double stranded break at a 
given locus, members of a ZFN pair must first bind their target DNA sequence, 
with each half of the pair binding to an opposite strand of DNA. This binding 
event brings the members of a ZFN pair into close enough proximity to allow for 
the formation of a catalytically active nuclease complex following dimerization of 
the nuclease domains, which then cleaves the underlying DNA sequence. ZFN 
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binding is highly specific, as cleavage will only occur if the ZFNs recognize and 
bind to an appropriate sequence, and the members of the ZFN pair bind in the 
correct orientation with a spacer requirement of 5-6 base pairs of DNA between 
each ZFP target sequence. Additionally, the FokI nuclease domain which 
normally functions as a homodimer, has recently been modified to function as a 
heterodimer by introducing charged residues at the nuclease dimer interface and 
placing these positively and negatively charged residues onto opposite sides of 
the monomers that comprise the FokI dimer(7). As two positively or negatively 
charged FokI monomers will not interact, these alterations allow the FokI 
nuclease to function as an obligate heterodimer, eliminating the possibility of 
one-half of a ZFN pair binding on opposite DNA strands at an off-target site and 
introducing an unwanted DSB(7).  
Despite their ability to target a wide array of sequences, ZFNs can be 
quite challenging to design owing in large part to the context-dependent nature of 
their DNA binding domains i.e. DNA triplet binding preference of each zinc finger 
domain in a ZFP array is influenced by any ZFPs to which it is directly linked. As 
such, early ZFP arrays used to design ZFNs displayed a high failure rate with 
many ZFNs failing to bind and cleave their target sequences. Recent 
improvements in the ZFN assembly platforms have made ZFN design somewhat 
easier, but these issues of context dependence and the relatively high cost of 
making ZFNs has led many groups to explore alternative platforms to accomplish 
precision genome editing. 
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III. Transcription Activator-Like Effector Nucleases  
TALENs bear a similar overall architecture to ZFNs in that they also 
function as a pair, with a DNA-binding protein domain fused to the nuclease 
domain of the FokI endonuclease. The TALEN DNA binding domain is based on 
the transcription activator-like (TAL) DNA-binding proteins found in Xanthomonas 
bacteria. Unlike ZFPs, the DNA binding of TAL effectors is almost entirely free of 
context dependent effects. Each TAL repeat usually consists of 33-35 amino 
acids, where all the residues are highly conserved except for residues in the 12 
and 13 position. Together these two amino acids are termed the repeat-variable 
diresidue (RVD) and they confer the nucleotide specificity of TAL effectors. 
Specifically, the 13th residue contacts a single nucleotide in the major groove of 
DNA while the 12th residue stabilizes the short loop structure formed by the RVD 
(8,9). As each RVD usually binds a single nucleotide, modular assembly of TAL 
repeats can be used to generate TAL protein arrays capable of binding any DNA 
sequence as long as that sequence begins with a Thymine base. While TALENs 
can also be used with obligate heterodimeric FokI nuclease domains, and can 
target long sequences to achieve genome-wide specificity as is done with ZFNs, 
they have a more variable spacer requirement than ZFNs, usually in the range of 
10-20bp and this could, in theory, contribute to an increased rate of off-target 
binding activity. Additionally, the repetitive nature of the TAL arrays makes them 
difficult to synthesize, and so while TALENs lack the context-dependent effects 
seen with ZFNs, their variable spacer lengths and challenging synthesis have 
hindered their widespread adoption. 
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IV. The CRISPR/Cas system 
The CRISPR/Cas system is the only known form of adaptive immunity 
against phage infection in prokaryotes, and is made up of two main 
components—arrays of clustered regularly interspaced short palindromic 
repeats (CRISPRs), and CRISPR associated (Cas) genes that are usually 
located adjacent to the CRISPR arrays.  Following phage infection, the 
CRISPR/Cas system functions by incorporating phage DNA into the host 
genome, synthesizing CRISPR RNAs (crRNA) with complementarity to the 
incorporated/invading phage DNA, forming crRNA-phage DNA hybrids, and 
degrading these hybrids through the nuclease activity of the Cas proteins 
(reviewed in (10)). Despite the diversity of bacteria and archaea with naturally 
occurring CRISPR/Cas systems, these systems all have the same overall 
architecture. CRISPR loci contain arrays of short nucleotide repeats separated 
by non-repeating spacer sequences. These spacer sequences, which are 
derived from invading phage, are called protospacers, and are flanked by short 
DNA sequences called protospacer adjacent motifs (PAMs).  There exist three 
main CRISPR/Cas systems—Type I, II and III, and of these the type II 
CRISPR/Cas system is arguably the most well studied. In this system, 
transcription at a CRISPR locus generates a pre-crRNA, which is then processed 
by Cas proteins into a crRNA containing, among other things, the phage derived 
protospacer sequence. This crRNA then binds a trans-activating crRNA 
(tracrRNA) and this complex guides sequence specific binding of the crRNA to 
the invading phage DNA and subsequent cleavage of the resulting RNA-DNA 
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hybrid by the Cas9 nuclease. Several recent studies have recreated the 
CRISPR/Cas system by generating a hybrid RNA—generally termed a guide 
RNA or gRNA(11-13). This gRNA has both complementarity to a target sequence 
located adjacent to a PAM sequence (similar to the crRNA), and a stem loop 
structure (similar to that present in the tracrRNA) that recruits the Cas nuclease 
(Cas9) to the site of the RNA-DNA complex. As such, co-delivery of a gRNA and 
a Cas9 encoding plasmid into a eukaryotic cell will result in the introduction of a 
DSB in a sequence-specific manner at any desired locus adjacent to a PAM 
sequence. A huge advantage of the CRISPR/Cas system is the ease with which 
gRNAs can be designed and used to effectively target a diverse array of 
sequences. Additionally, the gRNA is a relatively short oligonucleotide (usually ~ 
100bp), thus CRISPR/Cas gene targeting is generally more affordable than ZFN 
or TALEN mediated gene targeting. However, as CRISPRs do not have any of 
the specificity requirements built into the ZFN and TALEN architecture such as 
the binding requirement on opposite strands or the use of obligate heterodimeric 
nuclease domains, there remain concerns regarding their genome-wide 
specificity.  
V. Project goal I - Therapeutic applications of ZFNs to treat HIV 
	   To date, ZFNs, TALENs and CRISPR/Cas nucleases have been used to 
effectively target diverse genetic loci in cell lines and primary cells (including 
stem cells) (5,14-23). One of the earliest therapeutic applications of designer 
nucleases was the inactivation of a gene required for HIV infection in HIV-
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susceptible CD4 T cells (14). To infect a cell, HIV must first bind to its primary 
receptor CD4, and then to one of two coreceptors—CCR5 or CXCR4. As 
individuals with a naturally occurring inactivating mutation in ccr5 are highly 
resistant to HIV infection, this study attempted to replicate this phenotype by 
inactivating the ccr5 gene using ZFNs and showed that these gene-modified cells 
were both resistant to HIV infection and were selected for in the presence of 
viruses that use CCR5 to enter cells (14). This promising preclinical data led to 
one of the first human clinical trials involving a designer nuclease—the study of 
the autologous transfer of CCR5-ZFN modified CD4 T cells in HIV infected 
individuals (www.clinicaltrials.gov; Trial identifiers NCT00842634, NCT01044654, 
NCT01543152). While this trial holds great promise for a novel HIV treatment 
and a potential cure, if successful it would likely be most effective in patients that 
harbor viruses that exclusively use CCR5 to infect cells. As up to half of HIV-
infected individuals harbor viruses capable of using CXCR4 to infect cells (24), I 
sought to make this therapeutic application of ZFNs more broadly applicable in 
the first part of my thesis by using ZFNs to simultaneously inactivate both ccr5  
and cxcr4 in primary human CD4 T cells (Chapters 2 and 3). 
VI. Project goal II – Identification and characterization of sites of genome-
wide designer nuclease off-target activity  
  Although designer nucleases have the potential to change the way we 
treat diseases and perform research, we do not yet have a complete 
understanding of the genome-wide specificity of these nucleases or all the 
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factors that influence cleavage activity at unwanted sites. A number of studies 
have shown that while each designer nuclease exhibits a high level of cleavage 
activity at their target site, there is some level of unwanted cleavage activity at 
off-target sites. By searching the genome for sites with sequence similarity to the 
nuclease target site and analyzing these potential off-target sites for evidence of 
nuclease activity, several studies have identified some sites of off-target 
activity(14,15,25). However, while sequence similarity is likely a predictor of off-
target activity, there is mounting evidence suggesting that it is not the sole 
predictor of off-target activity (26). Additionally, there are currently no studies 
comparing the specificity of the three main classes of designer nucleases. Hence 
as part of my thesis, I attempted to identify sites of off-target activity for the three 
main classes of designer nuclease using a novel high-throughput assay to detect 
genome-wide translocations involving nuclease-induced double strand breaks 
(Chapter 4).   
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Chapter 2. Searching for a cure: HIV infection and novel treatment 
strategies 
I. The HIV epidemic: A persistent problem 
Since its identification as the etiologic agent of acquired immune 
deficiency syndrome (AIDS), human immunodeficiency virus (HIV) has claimed 
the lives of millions around the world. The introduction of antiretroviral therapy 
(ART) for HIV infection has dramatically altered the course of the HIV pandemic 
by delaying the progression to AIDS and increasing the lifespan of infected 
individuals (27-30), while decreasing HIV transmission rates (31-34). However, 
the prospect of eradication remains a distant one, as there are still 34 million 
people living with HIV worldwide, and more than 2 million new infections every 
year. Additionally, as the HIV infected population ages, we are learning that 
control of HIV infection by ART does not completely restore health (reviewed in 
(35)). Patients on ART remain at increased risk of developing cardiovascular 
disease compared to age-matched uninfected controls (36), and HIV infection 
also significantly increases the risk of developing kidney disease, osteoporosis, 
and a number of non-AIDS defining malignancies, even when patients are well 
controlled on ART (37-40). Moreover, ART itself is not without side effects, as 
certain classes of antiretroviral drugs directly contribute to some of these 
comorbidities. These HIV-associated morbidities that persist despite ART, the 
high cost of ART, and the requirement for daily adherence to ART to control 
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infection, all highlight the pressing need for strategies to achieve drug-free 
control and an eventual cure for HIV.  
II. Barriers to a cure: The HIV reservoir 
The major obstacle to achieving a cure stems from the fact that HIV not 
only infects and kills cells involved in combating infection (CD4 T cells), but also 
establishes a stable reservoir in these cells that goes undetected by the immune 
system (41-44). This latent reservoir is present in resting memory CD4 T cells, is 
largely unaffected by ART, and is responsible for the rapid rebound in viremia 
following ART cessation (43-47). As such, elimination of the reservoir is likely 
required for a cure.  Based on our understanding of HIV latency, it has long been 
thought that reactivation of the latent reservoir would result in the detection of 
infected cells and their subsequent destruction by the immune system. The 
pursuit of this “shock-and-kill” approach has led to the identification of 
pharmacologic compounds capable of reactivating latent HIV in vitro (reviewed in 
(48)), and there is evidence that one such drug, the histone deacetylase inhibitor 
vorinostat, is capable of disrupting HIV-1 latency to some degree in HIV infected 
individuals on ART (49). However, a recent study by Shan et al showed that 
following drug-induced reactivation of latency in CD4 T cells from patients on 
ART, these cells were not killed by autologous cytotoxic lymphocytes (CTLs), 
due to defects in the quality of the HIV-specific CTL response in ART-
experienced patients (50). These results suggest that pharmacologic reactivation 
of latency alone may not be enough to eliminate the reservoir. As such, there is a 
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need for alternative or complementary approaches that will enhance the ability of 
the immune system of HIV-infected persons to identify and kill cells harboring 
reactivated viruses if we hope to effectively eliminate the HIV reservoir using this 
strategy. A recent landmark study by Ho et al has also called into question our 
previous estimates of the HIV reservoir, and the ease with which the reservoir 
can be reactivated (51). This work stemmed from the observation that DNA 
measurements of the HIV reservoir size are up to 2-logs higher than 
measurements obtained using the standard viral outgrowth assay—an assay that 
estimates the reservoir size by measuring HIV production following maximum in 
vitro T cell activation of resting CD4 T cells from HIV-infected individuals (52). 
This difference in reservoir size estimates was initially believed to represent 
defective proviruses—a belief supported by the error-prone nature of HIV 
replication (53-58).  However, a careful characterization of these uninduced 
proviruses by Ho and colleagues revealed that up to 12% of them are actually 
genetically intact, integrate into active sites of transcription, and when 
synthesized, display replication kinetics comparable to those of latent viruses 
induced by T cells activation. This study has 2 major implications for the shock-
and-kill approach and the HIV cure field in general—the replication-competent 
HIV reservoir is considerably larger than previously thought, and reactivation of 
latent HIV is not determined solely by the activation state of a T cell, but may in 
fact be in part a stochastic process. 
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III. Gene therapy for a cure 
Genetic manipulation of long-lived primary CD4 T cells and hematopoietic 
stem cells (HSCs) to prevent HIV infection has long been viewed as a viable 
means of achieving ART-free control of infection, and following the recent report 
of a cure for HIV (59,60), there has been a surge of interest in exploring gene 
therapy-based approaches to treat HIV. This cure was achieved following an 
allogeneic hematopoietic stem cell transplant (HSCT) to treat leukemia in an HIV-
infected man, and was performed using cells from a donor bearing an 
inactivating mutation in both copies of the C-C chemockine receptor type 5 
(CCR5) gene—whose protein product is the primary HIV entry coreceptor 
(59,60). This mutation—known as ccr5∆32—confers resistance to HIV infection 
in homozygotes, and delays the progression to AIDS in heterozygotes (61-63). 
Following the transplant, the patient was taken off ART and in the ensuing years 
has remained free of HIV, with undetectable viral loads and substantial 
decreases in HIV-specific antibodies, suggesting that a cure has indeed been 
achieved. However, there remains a great deal of speculation regarding the 
reason for the cure. One possible explanation is that the complete donor 
chimerism achieved following allogeneic transplantation of CCR5-negative cells 
simply created an environment incapable of supporting HIV infection by 
eradicating all cells susceptible to infection with CCR5-using HIV. However, this 
may not fully explain the observed cure as the patient in question also had low 
levels of HIV capable of entering cells in a CCR5-independent manner by using 
the other HIV coreceptor C-X-C chemokine receptor type 4 (CXCR4), and yet 
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these viruses failed to expand following the transplant. That such viruses can 
expand in vivo in the face of selective pressure against CCR5 is evidenced by 
the fact that the most common cause of virologic failure following treatment with 
the CCR5 antagonist maraviroc is outgrowth of pre-existing CXCR4-using HIV 
strains (64,65). As such, alternative explanations for the cure including the role of 
graft-vs-host-disease (GVHD) in clearing the infection have been considered, 
with the assumption that the development of GVHD following the transplant led to 
the detection and donor cell-mediated clearance of all host immune cells 
including those cells harboring the latent HIV reservoir. Another potential reason 
for this remarkable cure is the destruction of the HIV reservoir by the conditioning 
chemotherapy and total body irradiation administered prior to the transplant. 
While such transplants have been performed in HIV infected patients in the past 
with no effect on their HIV infection, recent evidence suggests that allogeneic 
stem cell transplants with CCR5-positive cells may in fact have an effect on the 
size of the HIV reservoir as measured by the viral outgrowth assay(66).  
The striking resistance to HIV infection observed in ccr5∆32 homozygotes 
and the recent report of a cure following HSCT using ccr5∆32 cells has spurred 
several gene therapy efforts to block HIV infection at the level of entry in an 
attempt to reproduce this HIV-resistant phenotype in individuals lacking the 
delta32 mutation. As a result, several promising preclinical studies have 
successfully provided some form of protection against HIV by targeting infection 
at the level of entry and a number of these studies have been advanced to 
human clinical trials (Table 1). 
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IV. HIV Entry: The Basics  
The HIV life cycle begins with entry of the virus into susceptible cells. To 
enter a cell, HIV must first bind to its primary receptor CD4, and then to one of 
two coreceptors—CCR5 or CXCR4 (Figure 1) [5-13]. The choice of coreceptor 
used by the virus is intimately linked to disease acquisition and pathogenesis as 
the majority of transmitted viruses use CCR5 to enter cells [14-17], while the 
appearance of viruses capable of using CXCR4 during infection is associated 
with a more rapid progression to AIDS [18-21].  
Entry of HIV into target cells is mediated by the type I integral membrane 
viral glycoprotein Env. Env is synthesized as a polypeptide precursor termed 
gp160 which undergoes several of modifications within the cell as it is 
transported to the cell surface, including extensive N-linked glycosylation, and 
cleavage by cellular proteases into the extracellular gp120 and the membrane-
spanning gp41 subunits [27-29]. The extensive glycosylation of Env contributes 
to its ability to evade humoral immune responses, as the carbohydrate moieties 
covering its surface are poorly immunogenic and may shield potentially antigenic 
epitopes on the glycoprotein from recognition by the immune system [30-32]. 
Following gp160 cleavage—an event required for subsequent membrane 
fusion—gp120 and gp41 maintain their association via non-covalent interactions 
and are transported to the cell surface where they exist as a trimer of 
heterodimers that is ultimately incorporated into the viral membrane. Prior to CD4 
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binding—the first essential step in HIV entry—a number of cell-surface molecules 
are capable of mediating Env-dependent attachment of the virion to target cells. 
One such attachment factor is the C-type lectin CD209 or dendritic cell-specific 
intercellular adhesion molecule (ICAM) grabbing non-integrin (DC-SIGN). 
Expressed on dendritic cells, DC-SIGN and several other lectins are capable of 
binding Env and boosting infection in vitro by facilitating trans-infection of 
surrounding CD4 T cells by dendritic cell-bound virions (reviewed in [33]). More 
recently, monomeric gp120 from some HIV strains has been shown to bind the 
gut homing integrin α4ß7 [34,35], which is expressed on activated CD4 T cells. 
This finding is of particular interest as the depletion of CD4 T cells in the gut-
associated lymphoid tissue (GALT) early in infection is a hallmark of HIV disease 
[36-38] and ß7 integrins mediate trafficking of lymphocytes to the gut mucosa 
[39]. However, it is not clear whether α4ß7 supports binding of trimeric Env on 
the surface of virions, and thus its relevance to the gut pathology associated with 
HIV infection remains unknown. Furthermore, while interactions with these and 
other attachment factors influence HIV infection in vitro, little is known regarding 
their significance in vivo. 
The gp120 subunit of Env is composed of five relatively conserved (C1 – 
C5) and five more variable (V1 – V5) regions [40]. The conserved regions form 
the proximal core of gp120 while intrachain disulfide bonds in the variable 
regions of gp120 result in the formation of five variable ‘loop’ structures that 
make up the most exterior portion of the gp120 ectodomain [41]. The CD4 
binding site on gp120 is a well conserved cavity formed at the interface of the 
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inner and outer domains of the glycoprotein [42]. Following binding of gp120 to 
CD4, a series of conformational changes occur including the rearrangement of 
two pairs of ß-sheets from the gp120 inner and outer domains that come together 
to form a four-stranded ß-sheet structure termed the bridging sheet. The bridging 
sheet links the inner and outer domains of gp120 and interacts with the viral 
coreceptor, be it CCR5 or CXCR4 [42,43].  gp120 binding to CD4 also results in 
enhanced exposure and reorientation of the V1/V2 and V3 loops of gp120, 
outward rotation of each gp120 monomer to reveal the gp41 stalk, and hinge-like 
movements in CD4 that are thought to bring the viral membrane in close 
proximity to the target cell [42,44,45]. Together, all of these events culminate in 
the creation and exposure of the coreceptor-binding site. 
The HIV coreceptors belong to the family of chemokine receptors—seven-
transmembrane G-protein coupled receptors with prominent roles in immune cell 
trafficking. These receptors have three extracellular and intracellular loops, 
extracellular N-termini, and intracellular C-termini. While several different 
chemokine receptors are capable of mediating HIV entry in vitro, current 
evidence suggests that the CCR5 and CXCR4 chemokine receptors are the most 
frequently utilized in vivo [46-48]. Viruses capable of utilizing CCR5 alone, 
CXCR4 alone, or both coreceptors, are labeled R5-tropic, X4-tropic, and RX54 or 
dual-tropic viruses respectively. CCR5 is the primary coreceptor for the majority 
of HIV-1 isolates and is expressed on CD4 T-cell subsets, macrophages and 
dendritic cells, while CXCR4 is less commonly used, but is expressed on a wide 
variety of cells both within and outside the immune system [49]. For reasons that 
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remain unclear, the majority of transmitted viruses utilize CCR5 irrespective of 
the route of transmission and despite the availability of target cells expressing 
CXCR4 [17,50,51]. Multiple lines of evidence including mutational analyses, 
studies of small molecule inhibitors, and inhibition by coreceptor-specific blocking 
antibodies suggest that both the second extracellular loop (ECL2) and sulfated 
tyrosines within the N-terminus of the coreceptors interact with the V3 loop of 
gp120 and mediate coreceptor binding [52-57]. The V3 loop is also known to be 
a key determinant of coreceptor preference as the presence of positively charged 
amino acids at positions 11 and or 24/25 of V3 is correlated with CXCR4 usage 
[58,59]. 
The HIV fusion machinery is contained within the gp41 subunit of Env, 
which is comprised of a large cytoplasmic domain, a membrane-spanning 
segment, and an ectodomain that maintains contact with gp120. The ectodomain 
contains a typical fusion peptide—a stretch of hydrophobic amino acids at the N-
terminus [60,61]—along with two α-helical heptad repeats (HR), the N-terminal 
HR1 and the C-terminal HR2 repeats [62,63]. The current model of gp41-
mediated fusion is based on studies performed using HIV fusion inhibitors, 
crystal structures, and structural similarities between gp41 and other well-
characterized type I membrane fusion proteins including the influenza virus 
glycoprotein, hemagglutinin (HA) [63-66]. In this model, the sequential interaction 
of Env with CD4 and a coreceptor results in exposure of the fusion peptide, 
which then inserts into the plasma membrane of the host cell, causing gp41 to 
physically link both membranes. Subsequently, the three HR1 domains of the 
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Env trimer interact with one another to form a coiled coil, and the three HR2 
segments fold back on the HR1 trimer creating a six-helix bundle that brings the 
viral and host cell membranes in close contact with one another, allowing for 
mixing of the two membranes and formation of the fusion pore. Fusion between 
Env and the host cell was long thought to occur at the plasma membrane as HIV 
entry occurs in a pH-independent manner [67] and Env is capable of mediating 
fusion between neighboring cells, provided that they express CD4 and an 
appropriate coreceptor [68]. However, recent work using trans dominant-negative 
mutants of proteins involved in clathrin-mediated endocytosis [69] along with 
elegant studies using single-virion imaging [70] have demonstrated a clear role 
for components of the endocytic pathway in HIV entry in a number of cell lines. 
These studies were performed using immortalized cell lines, and as such, the 
role of the endocytic pathway in HIV entry into relevant cell types in vivo is yet to 
be determined.  
The cure achieved following allogeneic HSCT using ccr5∆32 cells 
highlights how our understanding of a very basic question—how a virus enters its 
host cell—has led to the development of new antiviral drugs and therapeutic 
approaches that have brought us a step closer to controlling the global HIV 
pandemic. 
 
	  
	  
19	  
VI. Pharmacologic inhibition of HIV entry 
The multi-step process by which HIV enters cells provides a series of 
unique targets for interventions to prevent viral entry including receptor and 
coreceptor binding, and membrane fusion. Efforts to inhibit these steps have led 
to the discovery of a new class of anti-HIV drugs—the HIV entry inhibitors 
(reviewed in [71]). A number of CCR5 inhibitors have been developed and 
display anti-HIV activity both in vitro and in vivo. These drugs are believed to 
work by binding to CCR5 at a site distinct from the gp120-binding site and 
subsequently alter the conformation of the CCR5 extracellular loops required for 
entry of R5-tropic HIV variants. One such CCR5 antagonist, maraviroc, is 
licensed for use in the United States and in Europe [43,72]. A variety of CXCR4 
antagonists have also been developed, and while they exhibit potent anti-HIV 
activity in vitro (against X4 but not R5 virus strains), administration of these drugs 
in vivo results in mobilization of HSCs from the bone marrow to the peripheral 
blood, highlighting the important role of CXCR4 in HSC homing [73-75]. Although 
this side effect limits their use in HIV-infected individuals, the CXCR4 antagonist 
plerixafor, is currently used to mobilize HSCs for subsequent autologous transfer 
in patients with non-Hodgkin’s lymphoma and multiple myeloma [76].  
gp41-mediated membrane fusion presents another drug target in the HIV 
entry process. Synthetic peptides based on the sequence of HR2 display 
significant antiviral activity against HIV in vitro but for many years, the 
mechanism of this antiviral activity remained unknown [77]. However, the 
	  
	  
20	  
observation that these peptides display higher antiviral activity as dimers and the 
elucidation of the structure of the gp41 fusion machinery have led to a model for 
their mechanism of action [63,64,78]. These drugs are now believed to act in a 
dominant negative fashion by competing with the HR1 and HR2 domains of gp41 
and ultimately preventing the formation of the six-helix bundle required for 
membrane fusion. One such peptide, enfuvirtide, is the only FDA-approved HIV 
fusion inhibitor, and is indicated for use in combination with standard 
antiretroviral therapy. However the twice-daily subcutaneous dosing schedule of 
the drug makes it an unattractive choice for many patients and care providers.  
As is the case for most anti-HIV drugs, viral variants resistant to all of the 
entry inhibitors have been identified. The appearance of maraviroc resistant 
viruses in vitro is a well-established phenomenon and these viruses either adapt 
to recognize the drug-bound conformation of CCR5, or more commonly, acquire 
the ability to use CXCR4 in addition to CCR5 (reviewed in [79]). In vivo, 
resistance to maraviroc most commonly results from outgrowth of pre-existing X4 
or R5X4 variants that are sometimes present at very low levels prior to the onset 
of therapy. As such, tropism testing is indicated prior to administration of 
maraviroc. In the case of enfuvirtide, mutations within HR1 and HR2 rapidly 
select for viruses with a dramatically decreased sensitivity to the drug [80,81]. 
HIV drug resistance is not unique to entry inhibitors, but is a widespread problem 
seen with all classes of HIV chemotherapeutics, and while ART increases 
survival in HIV-infected individuals, the problems of drug resistance, impaired 
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immune function despite ART, long-term financial cost and drug-associated 
toxicities of ART continue to fuel the search for curative therapies for HIV 
infection.  
 
VII. HIV entry as a target for gene therapy 
To date, several studies have explored genetic approaches to hijack or 
halt the 3 main steps of HIV entry—CD4 binding, coreceptor binding and 
membrane fusion. Outside of its role as the primary receptor for HIV, CD4 plays 
a critical role in antigen recognition by the T-cell receptor and as such, 
abrogation of CD4 expression is not a viable option to prevent HIV entry. A 
number of early gene therapy studies, however, took advantage of the fact that 
HIV-1 requires CD4 to enter cells, and coupled the extracellular and 
transmembrane domains of CD4 to the intracellular signaling domain of the 
invariant ζ-chain of the T cell receptor (TCR) thus pairing viral recognition by CD4 
with TCR signaling and downstream effector functions. Introduction of these 
chimeric receptors into CD4 and CD8 T cells resulted in HIV-specific targeting by 
both cell types in vitro. In particular, expression of these chimeric TCRs in 
cytotoxic CD8 cells allowed them to recognize and kill HIV infected cells which 
often express Env on their surface (67,68). Following these promising preclinical 
studies, two clinical trials investigated the effects of adoptive transfer of chimeric 
TCR modified CD4 and CD8 T cells on HIV infection. In both trials, the gene-
modified cells successfully engrafted and trafficked to the rectal mucosa—a 
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major site of HIV replication (69-71). While neither study observed a significant 
decrease in the viral load of treated subjects, one study reported a trend towards 
a decrease in reservoir size following treatment with the gene-modified cells(71). 
 To date, most gene therapy attempts to inhibit HIV entry have focused on 
interfering with the interaction between the virus and its coreceptors by either 
reducing or eliminating coreceptor expression. When attempting to genetically 
modulate coreceptor expression, an important consideration is the choice of cells 
to be treated as the ease with which target cells can be modified, and their 
longevity and capacity for self-renewal all influence the chances of success 
(reviewed in (72)). For this reason, most studies have focused on modifying 
either T cells or CD34+ HSCs with the eventual goal of adoptive transfer of the 
gene-modified cells. CCR5 is a particularly attractive target for HIV entry-focused 
gene therapy as the complete loss of CCR5 expression appears to be well 
tolerated in ccr5∆32 homozygotes. Additionally, the CCR5 small molecule 
antagonist maraviroc, which is currently approved for use in HIV infected 
patients, exhibits potent antiviral activity without adversely affecting immune cell 
function, suggesting that a partial or complete loss of CCR5 may not result in 
severe immunologic consequences (64,65). On the other hand, less is known 
about the potential consequences of decreasing or completely ablating CXCR4 
expression. In particular, CXCR4’s role in the bone-marrow retention of HSCs 
(73) may result in the unintended side effect of HSC egress from the bone 
marrow into the peripheral blood. 
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A number of studies have demonstrated the ability of exogenous 
transgenes to target the HIV coreceptors at the level of protein, RNA or DNA, 
with the final common result being decreased surface coreceptor expression. 
Early work using a CCR5-specific single-chain antibody engineered to express 
an ER-retention motif showed that these “intrabodies” prevented trafficking of the 
CCR5 protein to the cell surface. When introduced into susceptible cells, the 
resulting intrabody-mediated intracellular sequestration of CCR5 resulted in a 
decrease in infection by CCR5-using HIV (74,75). RNA-based approaches have 
also provided promising results—multiple studies have used RNA interference, 
CCR5-targeted ribozymes or a combination of both to efficiently decrease levels 
of CCR5 mRNA and thus surface expression of CCR5 (76-82). A recent clinical 
trial examined the safety and potential efficacy of one such RNA-based agent by 
following the adoptive transfer of autologous CD34+ stem cells transduced with a 
lentivirus encoding a CCR5 ribozyme, an anti-HIV siRNA and an RNA decoy that 
prevents initiation of HIV transcription (83).  In this study, the gene-marked cells 
engrafted successfully, and multiple hematopoietic lineages expressing the 
transgene were detectable for up to two years post-infusion. However, these 
cells did not provide any observable clinical benefit in terms of CD4 count or HIV 
viral load. While the lack of clinical benefit was likely in part due to the low 
percentage of gene-marked cells infused (~0.14% of infused cells were gene-
marked on average), another potential problem with this and other RNA-based 
gene therapy approaches to decrease CCR5 expression is their inability to 
completely and permanently eliminate surface CCR5 expression. This poses a 
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problem, as many HIV-1 isolates are capable of using low surface levels of 
CCR5 to enter cells. For this reason, many groups have begun exploring 
permanent modification of the host genome using designer nucleases so as to 
completely eliminate surface CCR5 expression.  
 CCR5-specific ZFNs are capable of permanently inactivating the CCR5 
gene in primary CD4 T cells, and ZFN-modification confers a survival advantage 
on gene-modified cells in the presence of CCR5-using HIV both in vitro and in a 
humanized mouse model of HIV infection (14). Additionally, ZFN modification of 
CCR5 in primary CD34+ HSCs results in the production of multiple hematopoietic 
lineages all lacking surface CCR5 expression (21). As a result of these promising 
preclinical data, several clinical trials are currently investigating the safety and 
efficacy of autologous transplants using ZFN-modified CD4 T cells or CD34+ 
HSCs in HIV infected individuals (www.clinicaltrials.gov; Trial identifiers 
NCT00842634, NCT01044654, NCT01543152). While these strategies are 
capable of generating cells that are highly resistant to infection with CCR5-using 
HIV, they offer no protection against viruses that use CXCR4. To this end, a 
recent study showed the ability of a ZFN pair targeting the CXCR4 coreceptor to 
specifically and efficiently inactivating this coreceptor in primary human CD4 T 
cells and in a humanized mouse model of HIV infection(15). However, in this 
study, protection of CD4 T cells in animals harboring CXCR4-modified cells was 
only transient, due to the outgrowth of viruses capable of using CCR5 to infect 
cells. These results, and the emergence of CXCR4-using HIV in patients who fail 
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treatment with the CCR5 antagonist maraviroc, highlight the importance of 
preventing both CCR5- and CXCR4-mediated entry in order to completely 
abolish infection by the two major HIV variants. 
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Chapter 3. Simultaneous zinc-finger nuclease editing of the HIV 
coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection 
 
Contributors to this work include Craig B. Wilen (UPenn), Jianbin Wang 
(Sangamo Biosciences), Jennifer Duong (Sangamo Biosciences), Anthony J 
Secreto (UPenn), Gwenn A. Danet-Desnoyers (UPenn), James L. Riley (UPenn), 
Phillip D Gregory (Sangamo Biosciences), Carl H. June (UPenn), and Michael C. 
Holmes (Sangamo Biosciences). 
 
I. Statement of hypothesis 
I hypothesize that the simultaneous inactivation of ccr5 and cxcr4 in T cell 
lines and primary human CD4 T cells is feasible. Additionally, I hypothesize that 
cells lacking both CCR5 and CXCR4 will have a survival advantage in the 
presence of both CCR5 and CXCR4-using HIV in vitro. Finally, I hypothesize that 
humanized mice bearing these double-gene modified cells will be better able to 
maintain their CD4 counts in the face of HIV-1 challenge as compared to wild-
type mice, or mice lacking a single coreceptor.  
 
II. Materials and methods 
Cell culture and ZFN treatment. SupT1 T cells expressing multiple copies of 
CCR5 introduced by lentiviral transduction (SupT1-R5), and primary human 
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CD4+ T cells were maintained in RPMI growth media (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS). CD4+ T cells were grown in the presence of 
human interleukin 2 (IL-2) (100 IU/ml). We used CCR5 (R5) and CXCR4 (X4) 
zinc finger proteins (ZFPs) from our previous studies(14,15). However, the ZFN 
nuclease domains were the ELD/KKR variant which were modified to function as 
obligate heterodimers with enhanced cleavage activity(84). To deliver ZFNs, we 
simultaneously transduced cells with two Ad5/F35 vectors encoding either the 
R5- or X4-ZFNs, or an Ad5/F35 GFP-expressing control vector(14,15). This is a 
chimeric adenoviral vector based on the AdEasy vector system (Promega) with 
an E1/E3 deleted backbone and a chimeric fiber gene comprised of a serotype 5 
fiber tail domain, and serotype 35 shaft and knob domains(85). CD4+ T cells 
were activated 18-24 hours prior to vector transduction with anti-CD3/anti-CD28 
coated magnetic beads(15) . We determined vector multiplicities of infection 
(MOIs) using the 293T cell line and measured mutation frequencies by surveyor 
nuclease (Cel1) or T7 Endonuclease I assay (T7E1), or deep 
sequencing(22,86,87). 
 
Virus production and infection. Pseudoviruses mediate one round of infection 
as the viral glycoprotein gene is only supplied in trans. We generated HIV 
pseudoviruses encoding a GFP reporter, bearing either the HIV glycoprotein 
(Env) or the Vesicular Stomatitis Virus glycoprotein (VSV–G) by co-transfection 
of the viral glycoprotein and the pNL4.3-Δenv-vpr+-eGFP-HIV backbone(88) into 
293-T cells using calcium phosphate. We harvested supernatants after 72 hours 
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and concentrated virus by ultracentrifugation(89). The HIV pseudoviruses were 
made using the R5 and X4-HIV envs JRFL and TYBE(90) respectively. For 
SupT1-R5 pseudovirus infections, we infected 1x105 cells in a 96-well v-bottom 
plate with 500ng of HIV-1 p24 or 5-10ng of HIV-VSV-G p24. Samples were spun 
at 1200xg for 90 minutes at 25°C then transferred to 37°C. Infection was 
measured at 96-hours by flow cytometric analysis of GFP positive cells.  
 Replication competent HIV-1 was made in primary CD4+ T cells (89) and 
we infected SupT1-R5 cells and primary cells with 50-100ng p24 per million cells 
5-7 days following ZFN treatment. The replication competent HIV-1 strains used 
were the R5-virus BaL, and the X4-viruses BK132 and HxB2. All CD4+ T cell 
infections were performed using cells from three independent donors. For all 
infections where cells were challenged simultaneously with R5 and X4-HIV, the 
viruses were mixed in a 1:1 ratio normalized by HIV-1 p24.  
 
Flow cytometry. Cells were stained at room temperature in Fluorescence-
activated cell sorting (FACS) buffer (PBS-/-, 2% FBS, 2mM EDTA). SupT1-R5 
cells and CD4 T cells were stained with Live/Dead Aqua and QD655-CD3 (clone 
S4.1)  (Invitrogen), Fluorescein isothiocyanate(FITC)-CD45 (clone H130) 
(Biolegend), AlexaFluor700-CD4 (clone RPA-T4), PacificBlue-CD8 (clone RPA-
T8), Allophycocyanin (APC)-CCR5 (clone 2D7) and Phycoerythrin (PE)-CXCR4 
(clone 12G5) (BD Biosciences). Samples were run on an LSR II (BD 
Biosciences), and analyzed using FlowJo 10.0.4 (Treestar).  
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HIV-1 humanized mouse challenge.  
12-14 week old NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj (NSG) immunodeficient mice 
received either unmodified CD4 T-cells, R5-ZFN-treated CD4 T-cells, or R5/X4-
ZFN-treated CD4 T-cells. Each group contained 18 animals and each animal 
received 1.8x107 cells. Mice were randomly assigned to control for cage, sex and 
birth cohort effects. The animals were maintained in a defined flora facility at the 
University of Pennsylvania, with approval of the Institutional Animal Care and 
Use Committee. We measured peripheral blood CD4 counts 21 days post-
infusion to assess engraftment by staining for CD45+/CD3+/CD4+/CD8- cells. 
Three days later, half the animals in each group received 5x104 CD4+ T-cells 
infected with the R5-virus BaL, and 5.0x104 CD4+ T-cells infected with the X4-
virus Bk132. Control animals received 1x105 uninfected CD4+ T-cells. We 
performed retro-orbital bleeds to assess CD4 counts and measure gene 
disruption. Mice were euthanized following the development of xenogeneic-graft-
versus-host-disease. Cardiac punctures and splenectomies were performed on 
all mice following euthanasia. We passed spleens through a 70µm strainer to 
obtain a single-cell suspension for measuring gene modification and CD4 count. 
ZFN-induced mutation frequencies were determined by performing deep 
sequencing at the R5 and X4-ZFN target sites(22). 
 
Off-target site analysis. We previously used systematic evolution of ligands by 
exponential enrichment (SELEX) to determine the in vitro binding preference of 
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each zinc finger protein (ZFP)(14,15). Using the information on CCR5 and 
CXCR4 binding preferences, we generated a position-weight matrix which we 
aligned to the human genome to look for sites with similarity to each of the four 
possible combinations of CCR5-CXCR4 cross heterodimers (R5-left with X4-
right; R5-left with X4-left; R5-right with X4-right; R5-right with X4-left). We 
allowed up to a 4bp mismatch compared to the SELEX consensus sequence, 
and considered sites with a 5bp or 6bp spacer between each ZFP pair. We 
performed deep sequencing at these sites to identify off-target activity(22). Off-
target activity was defined as an insertion/deletion (indel) involving the target 
region (20 bp) centered at the nuclease binding sites at a frequency of greater 
than 0.1%, and with a calculated ratio of cleavage (Z-M)/M of greater than 2, 
where Z represents % indels in ZFN treated samples, and M represents % indels 
in mock treated samples. 
 
III. Results 
Simultaneous ZFN disruption of ccr5 and cxcr4 in a T-cell line protects 
from R5 and X4-HIV infection 
 To determine whether two ZFN pairs targeting the HIV-coreceptors ccr5 
(R5) and cxcr4 (X4) could abolish expression of both coreceptors, we co-
transduced the human SupT1-R5 T-cell line with increasing amounts of the 
Ad5/F35 vectors encoding the R5-ZFN and X4-ZFN. Co-administration of both 
(R5/X4) ZFNs caused a dose-dependent reduction in cell surface expression of 
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both coreceptors with 9% of cells no longer expressing either coreceptor at the 
highest MOI, while delivery of the same vector encoding GFP had no effect on 
surface R5 or X4 levels  (Figures 3A-B). Next, we assessed the ability of ccr5 
and cxcr4 co-disruption to protect cells from infection with R5 and X4-using HIV-1 
strains. We challenged untreated or R5/X4-ZFN treated SupT1-R5 cells 
simultaneously with the R5- and X4-HIV strains BaL and BK132 respectively and 
monitored surface coreceptor expression for 42 days. The proportion of double 
(R5/X4) negative cells increased over the course of the infection such that by 25 
days post-infection, 96–99% of the R5/X4-ZFN treated cells challenged with HIV 
no longer expressed either coreceptor (Figure 3C-D). In contrast, the proportion 
of double-negative cells in the uninfected R5/X4-ZFN treated group did not 
change significantly over this time (Figure 3C, top panels). We also monitored 
cell viability and while untreated cells all died by ten days post-infection, a portion 
of the R5/X4-ZFN treated cells survived the infection with cell numbers 
increasing exponentially over time (Figure 3E). The coreceptor negative cells that 
survived HIV infection were re-challenged with pseudovirus bearing either HIV 
Env or VSV-G to confirm that the mechanism of resistance was due to inhibition 
of HIV Env-specific entry. These cells were highly resistant to either R5 or X4-
HIV pseudovirus re-challenge, displaying 170-fold and 92-fold decreases in 
reinfection with R5- and X4-HIV respectively (Figure 3F). Of note, low levels of 
residual infection (~0.1%) were observed in the R5/X4-ZFN group pre-challenged 
with HIV. However, the majority of this residual infection occurred in the 1-4% of 
cells still expressing CCR5 and CXCR4 (data not shown). Additionally, these 
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coreceptor negative cells were readily infected by HIV expressing the vesicular 
stomatitis virus glycoprotein (VSV-G HIV), a virus that is not dependent upon R5 
or X4 for infection (Figure 3F). Taken together, these data suggest that 
simultaneous delivery of two ZFN pairs is an efficient and viable strategy to 
disrupt ccr5 and cxcr4, resulting in cells resistant to infection with both R5 and 
X4-using HIV. 
 
ZFNs achieve simultaneous disruption of ccr5 and cxcr4 in human CD4+ T 
cells 
To determine the feasibility of this approach in primary cells, CD4+ T cells from 
healthy human donors were simultaneously transduced with the adenoviral 
vectors encoding the R5 and X4-ZFNs. Transducing cells with MOIs of up to 500 
of each ZFN resulted in modification of approximately 20% of all R5 and X4 
genes as measured by the Cel1 assay, without significant impact on cell growth 
compared to untransduced controls (Figure 4A-B). As surface expression of 
CCR5 is undetectable on most primary CD4+ T cells, we could not determine the 
proportion of cells lacking both coreceptors by flow cytometry. To exclude the 
possibility that co-administration of both ZFNs in primary cells results in R5 and 
X4 gene modification in mutually exclusive cells, we delivered both ZFNs to 
CD4+ T cells and sorted them by FACS based on surface CXCR4 expression 
into CXCR4-high and CXCR4-low populations (Figure 4C). We then measured 
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levels of R5 and X4 gene modification in both of these populations. While cxcr4 
gene modification was greatly reduced in the X4-high population following 
sorting, levels of ccr5 modification were similar in the X4-high and X4-low 
populations (Figure 4D), suggesting that adenoviral dual-ZFN treatment achieved 
dual-modification of ccr5 and cxcr4 in primary CD4+ T cells.  
Depletion of central memory CD4+ T cells is a hallmark of HIV pathogenesis and 
progression to AIDS(91). As such, protection of this long-lived subset is important 
for the success of any HIV gene therapy approach. We therefore determined 
whether central memory CD4+ T cells could be modified by the R5- and X4-
ZFNs. We first transduced CD4+ T cells with both ZFNs, expanded them in vitro 
for 10 days and then sorted the cells by FACS into central and effector memory 
populations based on surface expression of the memory markers CCR7 and 
CD45RO(92) (Figure 4E). CD4+ T cell activation using CD3/CD28 coated beads 
results in differentiation of ~97% of cells into a memory phenotype, with roughly 
half of all cells being either central or effector memory cells and the proportion of 
effector and central memory subtypes is not affected by treatment with the 
adenoviral vector or the ZFN (data not shown). We detected both ccr5 and cxcr4 
modification (Cel1) in the central memory (CCR7+, CD45RO+) and effector 
memory (CCR7-, CD45RO+) populations at similar levels (Figure 4E) suggesting 
that we can effectively target the coreceptors in these critically important T cell 
subsets. 
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Survival advantage of dual-ZFN treated CD4+ T cells in vitro 
To determine if the level of gene modification seen in primary cells rendered 
them resistant to both forms of HIV-1, we treated CD4+ T cells with both ZFNs, 
the R5-ZFN alone, or with a GFP control. We then challenged all three groups 
with a mix of R5- and X4-using HIV-1 and monitored cell growth and viability. By 
32 days post-infection, there were no detectable live cells in the groups that 
received either no ZFN or the R5-ZFN alone, whereas cells from the R5/X4 ZFN 
group continued to expand (Figure 5A). We measured levels of ccr5 and cxcr4 
gene modification 3 weeks into the infection in the R5/X4-ZFN treated group and 
observed increases in both ccr5 (1.8-fold) and cxcr4 (1.9-fold) gene modification 
(Figure 5B-C) when compared to the start of the infection. The preservation of 
cell growth and increases in gene modification seen only in the R5/X4-ZFN group 
in the presence of HIV suggest that ZFN-modification of both coreceptors 
provides a significant survival advantage in the presence of R5- and X4-using 
HIV.  
 
Analysis of off-target cleavage following dual ZFN administration 
 Simultaneous administration of two ZFN pairs creates the theoretical 
possibility of forming four different ZFN cross-heterodimers made up of the left 
and right halves of the two unique ZFN pairs. These ZFN cross-heterodimers 
may subsequently bind to unintended target sites, resulting in more off-target 
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gene modification compared to delivery of a single ZFN pair. As the target 
sequence contributes to ZFN binding and thus specificity(93), we previously 
determined the in vitro DNA binding preference of each CCR5 and CXCR4 ZFP 
using SELEX(14,15). We constructed a position-weight matrix for each 12bp ZFP 
binding site, and by comparing these sequences against the human genome to 
identify potential off-target binding sites, identified sites that were in fact 
independently cleaved by the R5- and X4-ZFNs(14,15).  In this study, we took a 
similar approach to identify off target sites that could result from the binding and 
cleavage of a ZFN heterodimer consisting of one half R5-ZFN and one-half X4-
ZFN. We performed deep sequencing at these predicted sites in primary CD4+ T 
cells following treatment with both the R5- and X4-ZFNs compared to otherwise 
identical untransduced controls (Table 2). Using genomic DNA from samples 
where on-target modification of ccr5 and cxcr4 were 28% and 20% respectively, 
we analyzed 4,000-20,000 reads per predicted off-target site but failed to detect 
significant levels of modification at any of the 40 predicted off-target sites (Table 
2). These results suggests that cross-heterodimerization of the R5- and X4-ZFN 
pairs following delivery to primary CD4+ T cells does not result in detectable off-
target activity, at the 40 sites examined. Moreover, the use of recently described 
orthogonal heterodimeric nuclease domains that further restrict cleavage (94) 
could further address this concern.  
 
	  
	  
36	  
Dual coreceptor disruption protects CD4+ T cells following HIV infection in 
vivo 
 NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj (NSG) immunodeficient mice are a useful 
model for studying HIV-1 in vivo as their immune systems can be reconstituted 
using human cells that are susceptible to HIV infection(95). To assess whether 
our approach protects against infection with both R5- and X4-HIV in vivo, we 
treated primary CD4+ T cells with no ZFN, the R5-ZFN alone or with the R5- and 
X4-ZFNs simultaneously. Three groups of 18 mice each were infused with 
1.8X107 cells per animal from each treatment group (Figure 6A). We observed 
CD4+ T cell engraftment across all groups 21 days post-infusion (Figure 6B). We 
then infected half the animals in each group by simultaneously infusing 5x104 
unmodified (no ZFN) CD4+ T cells infected with the R5-virus BaL and 5x104 
unmodified CD4+ T cells infected with the X4-virus BK132. Of note, while the 
BK132 HIV-1 swarm primarily uses CXCR4 to enter cells, it can also achieve 
very low levels of infection using CCR5(96) as evidenced by the outgrowth of R5-
HIV when this virus was used to challenge X4-ZFN treated CD4 T cells(15). Prior 
to infusion, the frequency of HIV p24+ cells was 58% and 44% in the R5 and X4-
HIV infected cells respectively. Control animals in each group received an 
infusion of 1x105 uninfected, unmodified CD4+ T cells. Animals that received R5-
ZFN or R5/X4-ZFN treated cells had 5.5 and 12.8-fold lower CD4 counts 
respectively, than animals that received untransduced cells when measured 
three days prior to infection (Figure 6B). However, this difference in CD4 counts 
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was no longer present at the time of the first peripheral blood sampling six days 
post-infection (Figure 6D). This slight engraftment difference was not seen 
previously (14,15) and may be donor specific. While CCR5 ablation alone was 
previously shown to protect against challenge with CCR5-using HIV(14),  animals 
that received both ZFNs were better able to maintain their CD4+ T cell counts 
following challenge with R5- and X4-HIV  (Figure 6D). Specifically, CD4 counts in 
animals from the infected R5/X4-ZFN group were 35 and100-fold higher than 
those in animals from the mock and R5-ZFN infected groups respectively by 22 
days post-infection, and these differences increased to an average 200-fold 
difference 55 days post infection (Figure 6D). Additionally, we measured the 
proportion of human CD4+ T cells in the spleens of infected animals at time of 
sacrifice. In animals that received dual-ZFN treated cells, up to 10% of all cells 
populating the spleen were human CD4+ T cells whereas we could not detect 
any human CD4+ T cells in spleens from animals that received either no ZFN or 
the R5-ZFN alone (Figure 6C).  
 To determine the mechanism of CD4 count maintenance observed in the 
R5/X4-ZFN group, we performed deep sequencing at the ZFN cut-sites in CD4+ 
T cells from animals in the R5/X4-ZFN group to measure changes in the 
proportion of ZFN-induced indels. There was no change in ccr5 or cxcr4 gene 
modification in uninfected animals that received both ZFNs. However, on 
average, 69% of all ccr5 genes and 73% of all cxcr4 genes were mutated in 
CD4+ T cells from the infected R5/X4-ZFN animals by 34 days post-infection 
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(Figure 7A). This represents a 2.2-fold increase in ccr5-modification and a 2.3-
fold increase in cxcr4-modification compared to six days post-infection. 
Additionally, we observed significantly lower surface expression of both 
coreceptors on cells from the infected R5/X4-ZFN treated mice 34 days post-
infection (Figure 7B). These data provide strong evidence that simultaneous 
disruption of ccr5 and cxcr4 using ZFNs is capable of generating a pool of cells 
that are resistant to the major forms of HIV in vivo, and these cells can engraft, 
traffic normally to the spleen, and have a significant survival advantage in the 
presence of R5- and X4-using HIV. 
 
IV. Discussion 
 Genetic approaches to control HIV infection have so far involved the 
removal of host genes required by the virus, or the introduction of antiviral genes 
that interfere with virus replication(72,97). While both are attractive options, the 
latter approach could be hampered by the potential immunogenicity of foreign 
transgenes and the diversity of the HIV viral quasispecies in chronically infected 
individuals, which may allow for the outgrowth of viral variants resistant to these 
antiviral genes. Removal of essential host factors such as the coreceptors, may 
present a greater challenge for the virus to overcome as suggested by the 
natural HIV resistance in ccr5∆32 homozygotes and the functional cure achieved 
following the transplantation of ccr5∆32 stem cells(59,60). Genetic editing 
through the use of coreceptor-specific ZFNs clearly renders a fraction of cells 
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coreceptor-negative, as HIV-1 challenge of ZFN-treated cells results in 
preferential survival of edited cells lacking the targeted coreceptor(14,15). 
Treatment with R5-specific ZFNs results in permanent modification of 30% and 
50% of ccr5 alleles in human hematopoietic stem cells and T cells 
respectively(14,22), with a bi-allelic modification frequency of up to half of 
that(22). The efficiency of bi-allelic disruption becomes even more important 
when attempting to disrupt both ccr5 and cxcr4, necessitating the inactivation of 
four genes in a given cell to render it resistant to infection by virtually all HIV-1 
strains.  
 Individuals lacking ccr5 do not display severe phenotypic abnormalities 
and its pharmacologic blockade is well tolerated(64), making it an ideal target for 
permanent modification. However less is known about the effects of the specific 
loss of CXCR4 expression on CD4+ T cells. One study has tried to address this 
by generating a T cell-specific knockout of cxcr4 in mice(98). These animals 
were born in normal numbers and displayed normal T cell function compared to 
wild-type mice, but displayed defective responses to the CXCR4 ligand, SDF-1.  
We have previously shown that our CXCR4-ZFN is capable of efficiently 
modifying CXCR4 in rhesus macaque cells, providing us with the unique 
opportunity of examining the engraftment and trafficking of CXCR4-ZFN edited 
CD4+ T cells in a more relevant model system before attempting this approach in 
humans(15).  
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 One potential limitation of this study is the modification of only CD4+ T 
cells and not a longer-lived cell population such as hematopoietic stem cells 
(HSCs). While previous studies have shown that ccr5 can be efficiently modified 
in CD34+ HSCs and this modification results in the production of ccr5 null CD4+ 
T cells and macrophages that are resistant to infection, CXCR4 signaling plays a 
critical role in the homing of HSCs to the bone marrow and as such, loss of 
CXCR4 expression on HSCs may result in their unwanted egress into the 
peripheral blood(73). However, due to the long half-life of memory CD4+ T cells, 
we believe that an approach consisting of modification of ccr5 in HSCs and both 
coreceptors in CD4+ T cells will provide patients with a pool of cells resistant to 
R5-HIV infection while at the same time preventing the outgrowth of viruses 
capable of using CXCR4.  
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CHAPTER 4. Translocation capture sequencing reveals the genome-wide 
specificity of ZFNs, TALENs and CRISPR/Cas associated nucleases 
Contributors to this work include Mary J. Drake (University of Pennsylvania), 
Nirav Malani (University of Pennsylvania), Craig B. Wilen (University of 
Pennsylvania) and Frederic Bushman (University of Pennsylvania)  
I. Introduction 
 Precision genome engineering allows for the introduction of stable, 
heritable genetic modifications into complex organisms in a sequence specific 
manner. These modifications are accomplished using one of the three main 
classes of designer nucleases—zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and clustered regularly interspaced 
short palindromic repeat (CRISPR) associated nucleases. Designer nucleases 
hold great promise for the treatment of human disease, but a high level of 
nuclease specificity is likely required to ensure that their use does not result in 
genotoxic effects. To this end, a number of studies have sought to identify sites 
of unwanted or off-target cleavage activity for each of these nucleases 
(14,15,25,99-103). However, most of these studies either employ approaches 
predicated on the assumption that sequence similarity is the primary driver of off-
target activity, or attempt to predict sites of off-target activity based on data 
obtained from in silico systems that may not faithfully recapitulate the DNA 
binding events that occur in a living cell. While all of these studies have identified 
sites of off-target activity with sequence similarity to the target site, a recent study 
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took a slightly different approach by co-administering a ZFN and an integration 
defective lentiviral vector, and showed that this vector was able to capture sites 
of ZFN-induced double strand breaks (DSB)(26). Using this approach the authors 
showed that ZFNs are able to cleave sequences with as low as 67% homology to 
their on-target sites and importantly, many sites with close to 100% homology to 
the ZFN target site showed no signs of nuclease activity (26). These results 
suggest that sequence specificity may not be the sole determinant of nuclease-
induced DNA double strand breaks (DSBs). We thus sought to unambiguously 
identify all nuclease induced DSBs in cells treated with each of the three main 
classes of designer nuclease using a more unbiased approach. We hypothesized 
that the simultaneous introduction of two DSBs within a cell by a designer 
nuclease—at on and off-target sites—may result in the formation of 
translocations between these sites, and we attempted to identify these 
translocations using Translocation Capture sequencing (TCseq). TCseq allows 
the high throughput identification of chromosomal rearrangements across the 
genome (104-107). Using this technique, a recent study showed that 
translocations in B-lymphocytes are associated with the rate of repeated site-
directed DNA damage (104-107). In this study, we set out to ask the following 
questions: (1) Do double strand breaks generated by a single designer nuclease 
at on and off-target loci result in the formation of translocations between these 
breaks? (2) Can these translocations be detected using TCseq? (3) Will the 
genome-wide characterization of the off-target sites involved in these 
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translocations further our understanding of the factors governing the specificity of 
these nucleases? 
II. Materials and methods 
Designer nucleases. In this study, we employed a CCR5-specific Compozr® 
Zinc Finger Nuclease (Sigma Aldrich) and a CCR5-specific XTN-TALEN 
(Transposagen Biopharmaceuticals). Both the ZFNs and TALENs encoded the 
ELD:KKR FokI nuclease domains with obligate heterodimeric FokI activity(84). 
CRISPR guide RNAs (gRNA) targeting the ccr5, cxcr4 and vegfa genes were 
designed based on the architecture described in (12), and the vegfa sequences 
targeted were previously described (103). We obtained a human codon-
optimized S. pyogenes Cas9 encoding plasmid from Addgene (Plasmid 41815). 
The Cas9 coding sequence was excised from pCDNA3.3 using XbaI and AgeI 
and blunt cloned into the BamHI site in the pGEM.64A vector. mRNA Transcripts 
derived from the resulting vector (termed pGEM.64A.hCas9) encode a 64-
nucleotide long polyA tail(108). Sequences targeted by the ZFNs, TALENs and 
gRNAs are as outlined in Table 3. 
 
In vitro transcription. To generate GFP, ZFN, TALEN, and Cas9 mRNA’s, 
plasmids encoding the respective mRNAs were linearized (XbaI for the ZFN left 
and right plasmids, PmeI for the TALEN left and right plasmids, SpeI for the 
pGEM.64A.hCas9 and pGEM.GFP.64A plasmids), and transcribed using the 
MEGAscript T7 in vitro transcription kit (Life technologies). Reactions were 
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performed at 37oC for 16 hours as per manufacturer’s instructions. To ensure 
proper capping of transcripts, transcriptions were performed using the 3´-0-Me-
m7G(5')ppp(5')G RNA Cap Structure Analog (New England Biolabs) at a 4:1 cap 
analog to GTP ratio. ZFN and TALEN plasmids were subsequently polyA-tailed 
using the A-plus Poly(A) Tailing Polymerase kit (Cellscript). To synthesize a 
gRNA mRNA targeting cxcr4, polymerase chain reaction (PCR) was used to 
simultaneously amplify the 100bp cxcr4 gRNA and add a T7 promoter to the 5’-
end of the PCR amplicon (Table 5). This amplicon was subsequently used as a 
template for T7 in vitro transcription without a cap analog, as described above. 
All mRNA transcripts were purified by lithium chloride precipitation. 
 
Cell culture and designer nuclease delivery. 293T cells were maintained in 
DMEM growth media with 10% fetal bovine serum (FBS). For each vegfa 
CRISPR transfection, triplicate wells of 4x105 293-T cells were plated in a 12-well 
plate. After 24 hours, these cells were transfected with either a GFP encoding 
plasmid (pHyg-EGFP, Clontech), or with 5ug each of two plasmids encoding the 
desired gRNA (pCRII Blunt TOPO) and the human codon-optimized S. pyogenes 
Cas9 (in pCDNA3.3) as previously described (12). Transfections were performed 
using Lipofectamine 2000 (Life Technologies) as per manufacturer’s instructions. 
Cells were transferred to a 6-well plate 24 hours post-transfection and were 
harvested 5 days post-transfection. Each condition was transfected in triplicate in 
each of two independent experiments. Genomic DNA from independent 
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experiments (~30 million cells per condition) was pooled for sequencing library 
preparation.  
Jurkat T cells (clone E6-1) were maintained in RPMI growth media 
(Invitrogen) supplemented with 10% FBS. ZFNs, TALENs, and CRISPR/Cas 
nucleases were delivered to Jurkat T cells by electroporation using a BTX-
ECM830 electroporator (Harvard apparatus BTX, Holliston, MA). Jurkat T cells 
were washed three times in OPTI-MEM (Invitrogen) and resuspended at a 
concentration of 1x108 cells/mL in OPTI-MEM. For each condition, ~1x107 cells 
were mixed with varying amounts of the corresponding nuclease mRNA or DNA 
(Table 5) and electroporated in a 0.2cm electroporation cuvette (500V for 700µs). 
Cells were immediately transferred to a 6-well plate containing pre-warmed 
RPMI+10%FBS at a concentration of 2x106 cells/mL and incubated at 30oC for 
24 hours. Following this, cells were maintained at a concentration of 1x106 
cells/mL for an additional nine days in a 37oC incubator prior to genomic DNA 
extraction for gene modification analysis and sequencing library preparation. For 
each condition, genomic DNA from 150-250 million cells obtained from three 
independent experiments was pooled for sequencing library preparation.  
 
Quantification of gene modification. Genomic DNA extractions were 
performed using the QIAamp DNA Blood Maxi kit (Qiagen) as per the 
manufacturers instructions. Mutation frequencies were measured as percent non-
homologous end joining (%NHEJ) using the T7 Endonuclease I assay (T7E1) as 
	  
	  
46	  
previously described (87). Primers used to perform the T7E1 assay are as 
outlined in Table 4. 
 
Translocation Capture sequencing 
Sequencing library preparation. For each sample, three 5µg aliquots of 
isolated genomic DNA were fragmented by enzymatic digestion using NEBNext 
dsDNA Fragmentase (New England Biolabs) to obtain a size distribution of 100-
1000bp. Fragmented genomic DNA was purified using the QIAquick PCR 
purification kit (Qiagen), and purified DNA was subsequently blunted using the 
Quick Blunting™ Kit (New England Biolabs), and adenosine-tailed using the 
klenow 3’ ! 5’ exonuclease (New England Biolabs). Each tailed fragment was 
ligated to a unique partially double-stranded DNA linker using a Quick ligation kit 
(New England Biolabs) to reduce sample contamination as previously 
described(109). Linker-ligated samples were pooled and amplified using Phusion 
DNA polymerase (New England Biolabs). We performed a first round PCR using 
a gene-specific primer located upstream of the nuclease induced double strand 
break, and a linker specific primer. A second PCR was performed using 1µl of a 
1/50 dilution of the first round PCR as a starting template. The second round 
PCR primers were internal to those used in the first round PCR and contained 
barcodes to allow for sample multiplexing, and sequences necessary for binding 
to an illumina sequencing flow cell as previously described (110). Library 
amplification primers are as outlined in Table 6. For Jurkat T cell samples, 8 
unique first round PCRs were performed and each of these was used as a 
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template for the second round PCR. For each 293T samples, two first round 
PCRs were performed and each of these was used as a template for four second 
round PCRs. All second round PCR samples were purified using the Agencourt 
Ampure XP beads (Beckman Coulter) and equimolar amounts of each sample 
were pooled to obtain a final sequencing library. 
 
Data analysis. Paired ends were rejoined and the sequence end originating 
within the nuclease-treated gene was aligned to the 30bp genomic sequence 
immediately following the sequencing primer, allowing for up to a 2bp mismatch. 
This sequence was then trimmed and the remaining sequence was aligned to the 
human genome using BLAST with a 90% identity criteria. Two or more reads 
were necessary to score a putative translocation event and translocation 
frequency was determined by analyzing the number of unique fragment lengths 
as previously described(109). 
 
Rearrangement verification. Nested PCR was used for both de novo 
identification and for verification of genomic rearrangements. Forward primers 
were always designed to anneal to the nuclease target gene upstream of the 
nuclease cut-site, while reverse primers were designed to bind the suspected 
translocation partner (Table 8). Second round PCR products were cloned into the 
pCR Blunt II TOPO vector using the Zero Blunt PCR TOPO kit (Invitrogen). 
Following transformation of cloned products individual colonies were analyzed by 
Sanger sequencing using the T7-primer included in the kit.  
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III. Results 
Activity of CCR5-specific ZFNs, TALENs and CRISPRs with an overlapping 
target sequence 
 To enable us compare the specificity of the three main classes of designer 
nucleases, we designed and obtained a ZFN, TALEN and CRISPR/Cas nuclease 
targeting an overlapping sequence in CCR5 (Figure 8A). Delivery of increasing 
amounts of these nucleases to the Jurkat T cell line resulted in a dose-dependent 
increase in the level of gene modification at the target loci (Figure 8B). 
Additionally, we simultaneously treated these cells with two CRISPRs—one 
targeting ccr5 and one targeting cxcr4—to determine whether simultaneous 
delivery of two designer nucleases resulted in an exponential increase in the rate 
of off-target cleavage, and to serve as a translocation control for future 
experiments. Using nested PCR and Sanger sequencing, we were able to 
identify reciprocal translocations between the ccr5 and cxcr4 loci involving the 
nuclease-induced double stranded breaks at these sites (Figure 9A-B) 
 
A single CRISPR/Cas nuclease generates rearrangements between sites of 
on and off-target activity  
 Several recent studies have identified sites of CRISPR/Cas nuclease off-
target activity(99,101-103). As such, we asked whether we could identify 
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rearrangements between these known on- and off-target loci. We employed two 
recently described CRISPRs targeting two unique loci in vegfa (termed 
VEGFA.T2 and VEGFA.T3). Delivery of either one of these nucleases to 293T 
cells results in gene modification at their respective target loci and at several off-
target loci (103) (Figure 10A). Thus we after delivering either nuclease to 293T 
cells, we used nested PCR in an attempt to identify rearrangements between 
these loci and their previously identified off-target sites. We assayed for 2 
rearrangements per CRISPR/Cas nuclease and were able to detect 
rearrangements of the expected sizes between all four on and off-target loci 
tested (Figure 10B). Using sanger sequencing, we confirmed that these 
rearrangements did in fact involve the expected loci (Figure 11A-D). 
 
IV. Discussion 
 In this ongoing study, we attempted to identify translocations involving 
designer nuclease-induced double strand breaks throughout the genome, in the 
hope that identification of translocation partners would reveal off-target double 
strand breaks caused by these nucleases. We have currently completed our 
deep sequencing of the nuclease-treated and control samples and are currently 
completing the analysis of this sequence data. However, our interim results prove 
that delivery of a single CRISPR/Cas nuclease results in the formation of 
detectable rearrangements between sites of on and off-target gene modification. 
As such, we expect that the results of our TCseq data analysis will be useful in 
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the identification of sites of designer-nuclease induced off-target activity across 
the genome. 
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CHAPTER 5. Conclusion and Future directions 
 The focus of this thesis was two-fold—to explore the feasibility of 
simultaneously inactivating the two entry factors necessary for infection by the 
major forms of HIV using one class of designer nucleases (ZFNs), and to 
develop a tool for the genome-wide identification of translocations caused by the 
major classes of designer nucleases in an attempt to better understand the 
factors influencing the specificity of these nucleases. 
 In the first project, we showed that simultaneous delivery of two 
ZFNs targeting the HIV entry coreceptors ccr5 and cxcr4 results in stable 
inactivation of these genes in primary human CD4 T cells—the primary target of 
HIV infection. We then went on to show that these gene-modified cells are 
protected from infection by viruses that use either CCR5 or CXCR4 to infect 
cells, and have a survival advantage in the presence of these viruses. Using a 
humanized mouse model, we showed that animals harboring cells that lacked 
both coreceptors were better able to maintain their CD4 counts following infection 
with viruses that use both coreceptors. In fact, following virus challenge, animals 
with the gene modified cells had greater than 100-fold higher CD4 T cell counts 
on average than animals with wild-type cells. Additionally, analysis of the gene-
modified cells following in vivo challenge revealed enrichment for gene-modified 
cells only in the presence of infection—supporting the hypothesis that knockout 
of both of these entry factors confers a survival advantage on primary CD4 T 
cells lacking these genes in the face of HIV infection. These results have 
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important implications for the field of HIV cure research. Specifically, our study 
has attempted to both phenocopy the remarkable cure achieved following the 
allogeneic transfer of stem cells from a ccr5∆32 homozygous donor to a wild-type 
HIV-infected recipient(59,111) and extend upon those results by generating cells 
resistant to HIV-1 viruses that  use either coreceptor (CCR5 or CXCR4) to infect 
cells. In this study, we utilized a humanized mouse model, which is a useful one 
for studying HIV infection in vivo. However, we will conduct future studies in a 
rhesus macaque infection model that more accurately recapitulates human HIV 
infection. The macaque model will allow for a more thorough investigation of the 
effects of our approach on HIV infection, including its effects on viral load, the 
DNA viral reservoir, and its ability to reconstitute the immune system—all in the 
setting of a prolonged antiretroviral therapy treatment interruption. In this model, 
we will also be better able to test the effect of loss of these coreceptors on T cell 
functionality by measuring the engraftment, trafficking, and longevity of these 
cells over an extended period of time in vivo. This model will also allow us to 
initially infect the animals, and subsequently perform an autologous transplant of 
gene-modified cells, to more closely mimic how this therapy will be administered 
in humans. Finally, this model will allow us test our long-term approach of 
modification of ccr5 in both CD34+ hematopoietic stem cells and CD4 T cells, 
and modification of cxcr4 in CD4 T cells alone. 
 Although inactivation of the viral coreceptors appears to be a logical 
approach to control HIV infection, what is less obvious is the amount of 
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coreceptor ablation required to observe a therapeutic effect. Data from ccr5∆32 
heterozygotes suggests that even partial coreceptor ablation may be of clinical 
benefit as these individuals display delayed disease progression following HIV 
infection(112).  As such, the current ZFN technology may provide a therapeutic 
benefit despite not completely eliminating coreceptor expression. In support of 
this, in a recent phase I study of HIV-infected patients who received autologous 
R5-ZFN modified CD4+ T cells, a number of these patients exhibited viral load 
decreases compared with pretreatment levels following a 12-week interruption of 
ART (Carl H. June, University of Pennsylvania, written communication, May 23, 
2013). Of note, the viral load in one of these patients reached undetectable levels 
prior to the reinstatement of ART and further analysis revealed this patient to be 
a ccr5∆32 heterozygote. Despite the modest number of patients enrolled in this 
study, it is tempting to speculate that even the relatively low levels of coreceptor 
ablation achieved by ZFN modification may be of therapeutic benefit, and that 
this benefit will only increase as the expression of either coreceptor is further 
reduced. 
A potential limitation associated with any approach that targets CCR5 
alone is the presence of virus strains that utilize CXCR4. Clinical failure 
associated with the use of the CCR5 antagonist maraviroc is either the result of 
an outgrowth of pre-existing virus strains that use CXCR4 and continue to 
replicate despite CCR5 blockade(65), or mutations that arise in the viral 
glycoprotein allowing it to use the drug-bound form of CCR5(113), a resistance 
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pathway not available to the virus when ccr5 is disrupted by ZFN technology. The 
fact that X4 HIV-1 strains can be present at low levels in chronically infected 
individuals provides a powerful rationale for employing a strategy that targets 
both ccr5 and cxcr4(114).  While R5 ZFNs have been used to ablate ccr5 in 
hematopoietic stem cells (HSCs) to provide a self-renewing population of CCR5 
negative cells, CXCR4 signaling plays a critical role in the bone marrow retention 
of HSCs(115,116). As a result, loss of CXCR4 expression on HSCs may result in 
their unwanted egress into the peripheral blood. Although less is known about 
the effects of the specific loss of CXCR4 expression on CD4 T cells, a recent 
study of T cell-specific cxcr4 knockout mice showed that these animals are born 
in normal numbers and display humoral and cellular responses indistinguishable 
from those of wild-type mice(98), suggesting that loss of CXCR4 expression on 
CD4 T cells may be immunologically tolerated.   
Our work and that of others provides compelling evidence for the ability of 
ZFN-mediated coreceptor ablation to protect CD4+ T cells and provide virologic 
control of HIV infections. However, a number of questions remain regarding the 
clinical efficacy of this approach and the ease with which it can be implemented. 
While the original transplant using ccr5∆32 cells resulted in a cure, other factors 
may have contributed to this outcome including reductions in reservoir size by 
the conditioning chemotherapy and graft-versus-host disease experienced by the 
patient. Allogeneic HSCT has long been known to exert an anti-tumor or graft vs 
tumor effect (117). While there is conflicting evidence on the effect of allogeneic 
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HSCT on HIV infection (reviewed in (118,119)), the idea that complete donor 
chimerism, if achieved following an allogeneic HSCT, would effectively cure an 
established HIV infection is an interesting one. For this to occur, the donor cells 
would likely need to be protected from infection during the transition to complete 
donor chimerism, and in the case of the ccr5∆32 transplant that resulted in a 
cure, that was achieved by using cells resistant to HIV infection. Another instance 
where protection of newly infused donor cells may have provided a clinical 
benefit in HIV infection is in the recent case of the ‘Boston patients.’ In this small 
study, three HIV-positive patients in Boston received allogeneic HSCT following 
reduced-intensity chemotherapy to treat lymphoma. The patients were kept on 
ART for up to 4 years following transplant and while only two patients survived, 
they were both shown to have a significantly lower viral reservoir as measured by 
viral outgrowth following maximum in vitro T cell activation (66). Moreover, these 
patients have recently undergone ART interruption and while results are only 
available for a few months post-ART interruption, there is no evidence of viral 
rebound as measured by viral RNA or DNA in the peripheral blood and rectal 
tissues of either patient [91].   This report is remarkable for two reasons—the 
cells used in the HSCT did not lack CCR5, and the procedure was performed 
with a reduced intensity chemotherapy regimen. This approach—if successful—
may sidestep some of the issues of HSCT toxicity related to chemotherapy, and 
the relatively low frequency of ccr5∆32 homozygous donors that has plagued 
attempts to repeat the success of the first cure. However, as the Boston patients 
have only been off ART for a short period of time, and prior HSCTs performed in 
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HIV-infected individuals who were subsequently placed on ART have not 
resulted in a cure (118,119), it remains to be seen whether the transplants have 
actually cured their infection or simply delayed the return of the virus. Of note, the 
patient who received a transplant using ccr5∆32 cells and both Boston patients 
who survived allogeneic HSCT with ccr5 wild-type cells were all ccr5∆32 
heterozygotes at baseline. At this time, however, it is not known whether their 
baseline ccr5∆32 heterozygosity could have provided any added benefit in the 
form of a smaller viral reservoir, or even a less severe course of their GVHD. 
[92,93]  
Although ART does not fully restore health, its introduction has resulted in 
a near-normalization of the life expectancy of HIV-infected individuals, and as 
such, future studies must determine whether ZFN treated cells can sufficiently 
control viral replication, restore normal immune function, and decrease the viral 
reservoir, as these features of HIV infection must be impacted if we hope to 
achieve a cure(48,120)—functional or otherwise—in HIV infected individuals. 
In the second part of my thesis, I set out to ask the following three 
questions: (1) Do double strand breaks generated by a single designer nuclease 
at on and off-target loci result in the formation of translocations between these 
breaks? (2) Can these translocations be detected using Translocation Capture 
sequencing (TCseq)? (3) Will the characterization of the off-target sites involved 
in these translocations further our understanding of the factors governing the 
specificity of these nucleases?  
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While this study is still ongoing, we were able to address our first question. 
Using nested PCR, we were able to identify rearrangements involving double 
strand breaks generated by a CRISPR/Cas nuclease at its on- and off-target loci. 
We hope that our TCseq analysis will provide much deeper insight into the 
genome-wide distribution of designer nuclease induced rearrangements. 
However, the identification of these rearrangements highlights two extremely 
important issues facing the field of precision genome engineering—the paucity of 
functional readouts of off-target activity, and the need to define an ‘acceptable’ 
level of off-target activity, if indeed such a thing exists. 
While several studies have identified sites of designer nuclease off-target 
activity, few have gone on to address the consequences of these off-target 
effects. This is in part due to the fact that a large proportion of these off-target 
modifications occur either in non-coding regions, in genes of unknown function, 
or occur at a relatively low frequency compared to the off-target site. And while a 
low level of modification in a non-coding sequence may be of little consequence, 
our work has shown that a single designer nuclease can result in translocations 
between protein-coding genes. The identification of these translocations provides 
us the unique opportunity to begin to probe the biological products of off-target 
gene modification. Specifically, we can begin to assess the oncogenic potential 
of designer nucleases by analyzing the rearrangements they produce and any 
fusion proteins that may result. Additionally, TCseq provides a rapid means of 
assessing the genome-wide specificity of any designer nuclease, and as such, 
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can be used to quickly determine whether improvements in nuclease architecture 
result in a decrease in genome-wide off-target activity. 
The second equally important issue highlighted by this study is the need to 
define an acceptable safety profile for a given designer nuclease. Early studies 
attempted to do this by using the in vitro toxicity of a nuclease as a readout for its 
safety. However, this approach likely overlooks a myriad of potentially genotoxic 
mutations whose phenotypes may not result in death, but may prove quite 
harmful in vivo. The benefits of our approach are two-fold—it may provide the 
most comprehensive analysis of genome-wide off-target profiles for any designer 
nucleases tested—and these profiles are linked to translocations that can be 
directly tested for biological activity. This functional readout may allow for the 
detection of clinically actionable rearrangements that occur following the delivery 
of a single designer nuclease. 
The field of genome engineering has huge potential for changing the way 
we grow crops, breed animals, and treat humans, and I hope that this thesis has 
yielded useful contributions to this burgeoning and exciting field. 
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Figures and Tables 
Table 1. Gene therapy clinical trials targeting the major steps in HIV entry 
 
 
  
Step%in%Entry%Targeted% Transgene/Payload% Target%cell% %%gene%marked%cells%at%study%conclusion% Reference%
CD4%binding% CD4$zeta)chimeric)T)cell)receptor))
Autologous)CD4+)and)CD8+)
T)cells)
0.1%)of)PBMCs)at)1)
year) 63)
CD4%binding% CD4$zeta)chimeric)T)cell)receptor))
Syngeneic)CD4+)and)CD8+)T)
cells)
0.1$1%)of)CD4+)and)
CD8+)T)cells)at)1)year) 64)
CD4%binding% CD4$zeta)chimeric)T)cell)receptor))
Autologous)CD4+)and)CD8+)
T)cells)
0.1$10%)of)PBMCs)at)
24)weeks) 65)
CCR5%binding% shRNA)targeMng)tat/rev,)TAR)decoy,)CCR5)ribozyme)
Autologous)CD34+)
HematopoieMc)stem)cells)
0.01%)of)whole)blood)
at)18)months) 77)
CCR5%binding% CCR5)speciﬁc)Zinc)Finger)Nuclease) Autologous)CD4+)T)cells) Completed)
hWp://clinicaltrials.gov/
ct2/show/
NCT00842634)
CCR5%binding% CCR5)speciﬁc)Zinc)Finger)Nuclease)(dose)escalaMon)) Autologous)CD4+)T)cells) Ongoing)
hWp://clinicaltrials.gov/
ct2/show/
NCT01044654)
CCR5%binding%
CCR5)speciﬁc)Zinc)Finger)
Nuclease)(dose)escalaMon,)
with)cyclophosphamide))
Autologous)CD4+)T)cells) Ongoing)
hWp://clinicaltrials.gov/
ct2/show/
NCT01543152)
CCR5%binding% CCR5)speciﬁc)Zinc)Finger)Nuclease)
Autologous)hematopoieMc)
stem)cells) Ongoing)
California)InsMtute)for)
RegeneraMve)Medicine)
grant)#)DR1$01490)
HIV%fusion% HIV)fusion)inhibitory)pepMde)maC46) Autologous)CD4+)T)cells)
Less)than)0.01%)of)
leukocytes)aaed)day)7) 86)
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Table 2. Indel frequency at predicted off-target sites following simultaneous treatment of 
primary CD4+ T cells with the R5- and X4-ZFNs 
 
	   	  
Arrangement Start*Site Site Chromosome Mismatches Gene Total*Reads %indels*(M) Total*Reads %indels*(Z) (Z;M)Indel% (Z;M)/M Conclusion Comments
R5ZFN&L_N5_R5ZFN&R 46414544 GTCATCCTCATCCTGATAAACTGCAAAAG chr33 0 CCR5 6033 0.10 5987 28.04 27.94 280.98 on3target
X4ZFN&L_N6_X4ZFN&R 136872909 CCACCCACAAGTCATTGGGGTAGAAGCGGTCA chr3 0 CXCR4 7836 0.14 6937 20.87 20.73 147.70 on3target
X4ZFN&L_N5_R5ZFN&R3 98297881 AGtCCGCTTCTAaAGAGTAAACTGCAtAAGT chr13 3 DPYD 12597 0.16 18538 0.18 0.02 0.12 no3activity
R5ZFN&R_N5_X4ZFN&L3 109228230 AaTTTTACGGTTaACAATGgAGAAGCGGTAC chr63 3 ARMC2 13042 0.09 14217 0.07 &0.02 &0.24 no3activity
X4ZFN&L_N6_R5ZFN&R3 27016543 AGACCGCTTCTAtATCCATAAAaTGGAgAAGA chr33 3 19337 0.01 20643 0.02 0.01 1.34 no3activity
X4ZFN&L_N5_R5ZFN&R3 21632080 GTGCCGgTTCTACCAGCTgAACaGGAAAAGC chr143 3 14143 0.11 14975 0.15 0.04 0.39 no3activity
X4ZFN&L_N6_R5ZFN&R3 1850892 ATGCCaCTTCTACCGAGACcAACTGGAAAtGA chrY3 3 12096 0.05 16228 0.01 &0.04 &0.75 no3activity
X4ZFN&R_N6_R5ZFN&L3 75770618 ACACCtCCAGGaCTACATGGcTGAGGATGAgG chr63 4 9270 0.01 8412 0.05 0.04 3.41 no3activity within3assay3noise
X4ZFN&R_N5_R5ZFN&L3 12941646 TCACCCCCAGtTCACCCTGAgGAGtAgGACG chr173 4 10491 0.35 12447 0.27 &0.08 &0.23 no3activity
X4ZFN&R_N5_R5ZFN&L3 71635397 GCACCtCCAAGTCCTCACGAgGAGGcTGAgA chr103 4 COL13A1 12581 0.14 18794 0.87 0.72 5.06 no3activity mostly3large3(40&80bp)3deletions,3likely3PCR3artifact
X4ZFN&R_N5_R5ZFN&L3 110885753 ACACCCtCgGGTCCTGCAGATGAGCcTGAgT chr133 4 COL4A1 2948 0.68 2541 0.12 &0.56 &0.83 no3activity
X4ZFN&R_N6_R5ZFN&L3 14425533 GCACCCCCtGGgtCTCCGGGATGAGGAgGACC chr193 4 8665 0.23 6073 0.33 0.10 0.43 no3activity
X4ZFN&R_N5_R5ZFN&L3 7279610 CCACCCACtAtTCCAGCTacTGAGGATGACT chr103 4 SFMBT2 6886 0.28 10020 0.15 &0.13 &0.46 no3activity
R5ZFN&L_N6_X4ZFN&R3 3238977 CcTCATCCTCAgCAGGCCTGgCTgGGGGGTGG chr113 4 4114 4.64 3224 4.47 &0.18 &0.04 no3activity mostly3large3deletions,3likely3PCR3artifact
R5ZFN&L_N6_X4ZFN&R3 43748539 CaTCATCCTCATCTTCAGCcACCTGTGGGcGG chr13 3 C1orf210 7212 0.60 4421 0.54 &0.05 &0.09 no3activity
X4ZFN&R_N5_R5ZFN&L3 49133212 TCACCCgCAAGTCCCAGAGtTGAGGcTGACA chrX3 3 PPP1R3F 4315 0.28 5128 0.33 0.05 0.19 no3activity
R5ZFN&L_N6_X4ZFN&R3 43421403 TcTCATCCTCAgCACCGTTGACCTtTGGGaGC chr123 4 14699 0.03 15132 0.02 &0.01 &0.42 no3activity
X4ZFN&R_N5_R5ZFN&L3 8681224 GaACCCACAGGTCACCGAGAaGAGCATcACC chr83 3 MFHAS1 3888 0.08 4260 0.02 &0.05 &0.70 no3activity
R5ZFN&L_N6_X4ZFN&R3 128765042 TcTCATtCTCATCCCCTGTGACTTGGcGGTcC chr113 4 KCNJ5 10649 0.08 20127 0.04 &0.03 &0.40 no3activity
R5ZFN&L_N6_X4ZFN&R3 71871779 GGTCATCCTCAgCAGAGTGGACTaaGGGGTcC chr173 4 14648 1.65 11586 0.47 &1.18 &0.72 no3activity mostly3large3deletions,3likely3PCR3artifact
R5ZFN&R_N6_X4ZFN&R3 92737093 AaTTTTGCAaTTaAAATGGGACTTGGGGGTGA chr93 3 4238 0.17 3712 0.27 0.10 0.63 no3activity
R5ZFN&R_N6_X4ZFN&R3 36865579 TCTTTTAtGGTTTCGGTTGGAaTTGTGGGTGG chr133 2 C13orf38 10186 0.01 17088 0.05 0.04 4.36 no3activity within3assay3noise
R5ZFN&R_N5_X4ZFN&R3 2796248 TCTTTTCtAGTTTCCTCTGACCTGTGGGTtG chr63 2 9217 0.03 7702 0.04 0.01 0.20 no3activity
R5ZFN&R_N6_X4ZFN&R3 99258148 CCTTTTGCAGTTTCTGCTGGACaTcaGGGTGA chr73 3 CYP3A5 7999 0.24 8135 0.25 0.01 0.04 no3activity
R5ZFN&R_N5_X4ZFN&R3 102430357 TCTTTTTCGGTTTTGTGTGAaTcGTGGGTGT chr63 2 GRIK2 12758 0.29 12006 0.42 0.13 0.46 no3activity mostly3large3deletions,3likely3PCR3artifact
X4ZFN&R_N6_R5ZFN&R3 25532770 CCACCCCCAAGTCCCTTTTAcACTaCAAAAaT chr33 3 RARB 11035 0.42 9146 0.31 &0.11 &0.27 no3activity
R5ZFN&R_N6_X4ZFN&R3 175289032 TCaTTTCaGGTcTTCTATGGACTTGTGGGTGG chr33 3 NAALADL2 13488 0.08 16734 0.14 0.06 0.76 no3activity
X4ZFN&L_N6_R5ZFN&L3 103817758 ATGCCGCTTCTgCCTGCAAGATGAGaAaGACA chr83 3 5667 0.02 6578 0.05 0.03 1.58 no3activity
X4ZFN&L_N6_R5ZFN&L3 141380550 AGACaGCTTCTACCATGTGGATGAGGAcaACA chr73 3 KIAA1147 12880 0.17 9524 0.06 &0.11 &0.63 no3activity
R5ZFN&L_N6_X4ZFN&L3 85231512 TcTCtTCCTCATCCACTTGcTAGAAGCaGTCC chr13 4 9306 0.03 8144 0.06 0.03 0.90 no3activity
R5ZFN&L_N6_X4ZFN&L3 68402483 AGTCATCCgCATCCACCAAGTAGAAGgGGaAA chr123 3 6868 0.16 8244 0.29 0.13 0.82 no3activity
R5ZFN&L_N6_X4ZFN&L3 105663998 CcTCcTCCTCcTCCTCCTAGTAGAAGCtGCAC chr73 4 FLJ23834 3485 16.24 4769 18.87 2.63 0.16 no3activity likely3PCR3artifact3due3to3presence3of3repeated3short3sequence3"CCT"
R5ZFN&L_N6_X4ZFN&L3 129253775 GGTCAgCCTCATCCCATGCGTtGAAGaGGCCT chr103 3 13892 0.13 14547 0.34 0.21 1.60 no3activity
X4ZFN&L_N6_R5ZFN&L3 763557 ATcCCGCaTCTACGCCAGTGAgGAGGATGACT chr193 3 C19orf21 9110 3.30 5441 4.30 1.00 0.30 no3activity mostly3large3deletions,3likely3PCR3artifact
X4ZFN&L_N5_R5ZFN&L3 42517731 AGGCCGCTTCTACTTACGGcTGAaGAgGAaG chr83 4 3877 0.15 6052 0.08 &0.07 &0.47 no3activity
R5ZFN&L_N5_X4ZFN&L3 180652373 TGTCcTCCTCtTCAACTCGTtGAAaCGGTCT chr23 4 ZNF385B 5346 0.06 8293 0.05 &0.01 &0.14 no3activity
X4ZFN&L_N5_R5ZFN&L3 90025463 GCACCGCTTtTACAAGGAGAaGAGCAaGAgC chr163 4 DEF8 9942 0.03 10837 0.06 0.03 1.14 no3activity
R5ZFN&L_N5_X4ZFN&L3 68589345 GGTCATGCaCcTCACTCAGTAGAAGgGGCCA chr163 3 ZFP90 13813 0.04 12597 0.02 &0.01 &0.34 no3activity
X4ZFN&L_N6_R5ZFN&L3 30834644 AGACCaCTTgaACTAATAGGAgGAGGATGACG chr23 4 LCLAT1 8239 1.27 8538 0.62 &0.65 &0.51 no3activity
X4ZFN&L_N6_R5ZFN&L3 9859397 ACGCtGCTaCTgCCTGGGGGcTGAGGATGACA chr33 4 TTLL3 7200 0.18 5330 0.26 0.08 0.45 no3activity
X4ZFN&L_N5_R5ZFN&L3 125124276 TGGCaGCTTCaACCTGCAGATGAGCAaGAaC chr33 4 13684 0.07 20006 0.02 &0.05 &0.70 no3activity
X4ZFN&L_N5_R5ZFN&L3 242334646 GCtCCtCTTCTACTTAGAGcaGAGGATGACT chr23 4 FARP2 6502 0.29 9157 0.32 0.02 0.08 no3activity
N5/N63refers3to3the3length3of3the3spacer3between3the323members3of3the3ZFN3pair3ie3either353or36bp
(Z&M)/M3needs3to3be3>=23to3be3considereded3as3specific
Lowercase3letters3in3sequence3indicate3base3mismatches
Mock*treated*samples R5/X4;ZFN*treated*samples*
(MOI_500/500)
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Table 3. Sequences targeted by ZFNs TALENs and CRISPRs used in this study 
Plasmid Target gene Target sequence 
PZFN1 CCR5 ACCTGCAGCTCTCAT 
PZFN2 CCR5 ATACAGTCAGTA 
TAL-left CCR5 TTCATTACACCTGCAGCT 
TAL-right CCR5 AGTATCAATTCTGGAAGA 
CCR5.gRNA CCR5 ATACAGTCAGTATCAATTCTGG 
CXCR4.gRNA CXCR4 TTCTACCCCAATGACTTGTGGG 
VEGFA.T2.gRNA VEGFA GACCCCCTCCACCCCGCCTCCGG 
VEGFA.T3.gRNA VEGFA GGTGAGTGAGTGTGTGCGTGTGG	  
 
Protospacer–adjacent motif (PAM) sequences are noted in bold) 
 
Table 4. T7E1 and transcription template preparation primers 
 
Gene 
target 
Forward 
primer 
name 
Forward primer sequence 
Reverse 
primer 
name 
Reverse primer 
sequence Use 
CCR5 R5.T7E1.F* TTAAAAGCCAGGACGGTCAC R5.T7E1.R* 
TGTAGGGAGCCCAGAA
GAGA T7E1 
CXCR4 X4.T7E1.F* CAACCTCTACAGCAGTGTCCTCATC X4.T7E1.R* 
GGAGTGTGACAGCTTG
GAGATG T7E1 
VEGFA.
T2 
VT2.T7E1.F
* AGAGAAGTCGAGGAAGAGAGAG 
VT2.T7E1.R
* 
CAGCAGAAAGTTCATGG
TTTCG T7E1 
VEGFA.
T3 
VT3.T7E1.F
* TCCAGATGGCACATTGTCAG 
VT3.T7E1.R
* 
AGGGAGCAGGAAAGTG
AGGT T7E1 
CXCR4 
gRNA 
X4.T7.gRNA
.F** 
GAAATTAATACGACTCACTATAGTTCTACCCCA
ATGACTTGTG 
X4.T7.gRNA
.R** 
GCACCGACTCGGTGCC
ACTTT  
T7 
promo
ter 
additio
n 
 
*CXCR4, VEGFA.T2 and T3 primers were previously published; CCR5 primers were obtained 
from Sigma Aldrich Compozr ZFN kit 
**Underlined sequence is T7 promoter, Bold sequence is CXCR4 gRNA sequence 
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Table 5. Nuclease doses and delivery methods used in study 
Cell 
Type 
Gene 
target Nuclease type 
Nuclease delivery 
method 
Nuclease 
dose 
Nuclease 
amount (μg) 
Jurkat None (GFP) mRNA 
BTX 
electroporation 
Single 
dose 10μg GFP 
Jurkat CCR5 ZFN mRNA BTX electroporation Low 
2μ-left/2μg-
right 
Jurkat CCR5 ZFN mRNA BTX electroporation Medium 
10μg-left/10μg-
right 
Jurkat CCR5 ZFN mRNA BTX electroporation High 
20μg-left/20μg-
right 
Jurkat CCR5 TALEN mRNA BTX electroporation Low 
2μ-left/2μg-
right 
Jurkat CCR5 TALEN mRNA BTX electroporation Medium 
10μg-left/10μg-
right 
Jurkat CCR5 TALEN mRNA BTX electroporation High 
20μg-left/20μg-
right 
Jurkat CCR5 Cas9-mRNA/CCR5 gRNA-DNA 
BTX 
electroporation Low 
10μg Cas9/2μg 
gRNA 
Jurkat CCR5 Cas9-mRNA/CCR5 gRNA-DNA 
BTX 
electroporation High 
10μg Cas9/4μg 
gRNA 
Jurkat CCR5 & CXCR4 
Cas9-mRNA/CCR5 
gRNA-DNA/CXCR4 
gRNA-mRNA 
BTX 
electroporation 
Single 
dose 
20μg Cas9/2μg 
CCR5 
gRNA/2μg 
CXCR4 gRNA 
293T None (GFP) DNA 
Lipofectamine 
2000 
Single 
dose 10μg GFP  
293T VEGFA.T2 Cas9-DNA/gRNA-DNA 
Lipofectamine 
2000 
Single 
dose 
5μg Cas9/5μg 
gRNA 
293T VEGFA.T3 Cas9-DNA/gRNA-DNA 
Lipofectamine 
2000 
Single 
dose 
5μg Cas9/5μg 
gRNA 
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Table 6. Gene-specific amplification primers used in sequencing library preparation 
Primer name Primer sequence Notes 
CCR5 primer F1 GTGGCTGTGTTTGCGTCTCT 
Round 1 
PCR 
CCR5 primer F2.1 
CAAGCAGAAGACGGCATACGAGATATCACGAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.2 
CAAGCAGAAGACGGCATACGAGATCGATGTAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.3 
CAAGCAGAAGACGGCATACGAGATTTAGGCAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.4 
CAAGCAGAAGACGGCATACGAGATTGACCAAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.5 
CAAGCAGAAGACGGCATACGAGATACAGTGAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.6 
CAAGCAGAAGACGGCATACGAGATGCCAATAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.7 
CAAGCAGAAGACGGCATACGAGATCAGATCAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.8 
CAAGCAGAAGACGGCATACGAGATACTTGAAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer F2.9 
CAAGCAGAAGACGGCATACGAGATGATCAGAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
CCR5 primer 
F2.10 
CAAGCAGAAGACGGCATACGAGATTAGCTTAGTCAGTCAGCCTCCCAGGAATCATCT
TTACCA 
Round 2 
PCR 
VT2.T7E1.F AGAGAAGTCGAGGAAGAGAGAG 
Round 1 
PCR 
VEGFA.T2.F2.illu
mina.1 
CAAGCAGAAGACGGCATACGAGATTCCCTTGTCTCCAGTCAGTCAGCCCCCCAGCTA
CCACCTCCT 
Round 2 
PCR 
VEGFA.T2.F2.illu
mina.2 
CAAGCAGAAGACGGCATACGAGATACGAGACTGATTAGTCAGTCAGCCCCCCAGCTA
CCACCTCCT 
Round 2 
PCR 
VT3.T7E1.F TCCAGATGGCACATTGTCAG 
Round 1 
PCR 
VEGFA.T3.F2.illu
mina.1 
CAAGCAGAAGACGGCATACGAGATACGAGACTGATTAGTCAGTCAGCCGCAGACGG
CAGTCACTAGG 
Round 2 
PCR 
VEGFA.T3.F2.illu
mina.2 
CAAGCAGAAGACGGCATACGAGATGCTGTACGGATTAGTCAGTCAGCCGCAGACGG
CAGTCACTAGG 
Round 2 
PCR 
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Table 7. Linker amplification primers used in sequencing library preparation 
Primer 
name Primer sequence Notes 
L1 PCR1 CGCACCCAGTATTCAACAGGTA Round 1 PCR 
L2 PCR1 GTTTGAGATGCCTACGCCATCC Round 1 PCR 
L3 PCR1 TGGTCGGCGAACAATAGTGGTT Round 1 PCR 
L4 PCR1 TTCAGGAGGTCACTTCGCACAT Round 1 PCR 
L6 PCR1 TAGACCGCTCAGAGGTCATACT Round 1 PCR 
L7 PCR1 CATCGTCGACACACGTGATGAC Round 1 PCR 
L8 PCR1 TATGCGGGACAGGTAATACGCG Round 1 PCR 
L9 PCR1 GGAATCTATGTAGCAGGTCGCT Round 1 PCR 
L10 
PCR1 CGCTTTGAGCTATGAACCCTAT Round 1 PCR 
L11 
PCR1 AATGCGACACGCATCCTGATTT Round 1 PCR 
L12 
PCR1 ATTGAAGGATCCGCCTCTCTAT Round 1 PCR 
L13 
PCR1 GAGTCGAATGGTGTATACCTCA Round 1 PCR 
L14 
PCR1 TTATTGCGGTAGTGAGGAAGGT Round 1 PCR 
L15 
PCR1 GAATCCAGTAAGATCCGTGTGT Round 1 PCR 
L1 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTGTAGT
TCCTCGGATCATGTCA Round 2 PCR 
L2 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTCCGG
TCTCTCATTAACTGGA Round 2 PCR 
L3 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTGTTGA
ACGGACAGATTAGTGC Round 2 PCR 
L4 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTCATTG
CTTCTTCCCACTAGAG Round 2 PCR 
L6 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTACTTG
CACTTCTGACCTAGCT Round 2 PCR 
L7 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTGACGA
GTCAGTCCTACTAAAG Round 2 PCR 
L8 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTACGCG
AGCCAGACTCCATATT Round 2 PCR 
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L9 PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTCGCT
AGAGTACGGCCTTGAA Round 2 PCR 
L10 
PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTATTG
AGAGAGGGAAAGAGGC Round 2 PCR 
L11 
PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTTTCG
GGCCTGATTTACTTCG Round 2 PCR 
L12 
PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTATTG
TTTGAAGGGACGCACG Round 2 PCR 
L13 
PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTCTCAC
CCGTTCTGGAGACTT Round 2 PCR 
L14 
PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTAGGTC
GAGTCTTGGGTAGGT Round 2 PCR 
L15 
PCR2 
primer 
AATGATACGGCGACCACCGAGATCTACACCAGGACTGACGCTATGGTAATTGTTGTGT
CTGCTTCCGCATCAGT Round 2 PCR 
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Table 8. PCR Primers used for nested PCR to detect rearrangements.  
Primer name Primer sequence 
VEGFA.T2.F PCR1 AGAGAAGTCGAGGAAGAGAGAG 
VEGFA.T3.F PCR1 TCCAGATGGCACATTGTCAG 
VEGFA.T2.F PCR2 ACAGGGGCAAAGTGAGTGAC 
VEGFA.T3.F PCR2 GAAGCAACTCCAGTCCCAAA 
VEGFA.OT2-1.R 
PCR1 TGCTCTGGATAAAGCACAAA 
VEGFA.OT2-1.R 
PCR2 ACTGATCGATGATGGCCTATGGGT 
VEGFA.OT2-2.R 
PCR1 TCCTGTCACAATTCCCTGAA 
VEGFA.OT2-2.R 
PCR2 GCAGCCTATTGTCTCCTGGT 
VEGFA.OT3-2.R 
PCR1 GGTTTCTTCCGGGATTTGTA 
VEGFA.OT3-2.R 
PCR2 TACCCGGGCCGTCTGTTAGA 
VEGFA.OT3-18.R 
PCR1 CACTGAAGCAGAGAGTAGAATGG 
VEGFA.OT3-18.R 
PCR2 GTTGCCTGGGGATGGGGTAT 
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Figure 1. Designer nuclease mechanism of action. (A) Architecture of zinc finger nucleases 
(ZFNs) and Transcription activator-like effector nucleases (TALENs). In a ZFN, each ZFP binds 
3-4 base pairs of DNA, while each repeat divariable residue (RVD; colored squares, top right 
panel) binds a single nucleotide. (B) Schematic depicts binding of a Cas9/crRNA/tracrRNA 
complex to a target sequence (protospacer) (C) Depiction of the events following the introduction 
of a double strand break which result in genomic alterations—gene disruption following incorrect 
repair by non-homologous end-joining, gene correction or gene substitution following repair by 
homologous recombination. Image adapted from Current Opinion in Plant Biology, Vol 16/ Issue 
2, Hao Chen,Yongjun Lin, Promise and issues of genetically modified crops, 255-260 Copyright 
(2013), with permission from Elsevier.  
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Figure 2. The HIV Entry Process involves the CD4 receptor, and CCR5 or CXCR4 
coreceptors. The figure below outlines a model for HIV Entry. The entry process begins with 
binding of gp120 (red) to its primary cellular receptor CD4 (green). CD4 binding results in 
conformational changes that allow binding of gp120 to the coreceptor—either CCR5 or CXCR4. 
Coreceptor binding results in triggering of the fusion machinery and formation of the six-helix 
bundle required to drive fusion of the viral and host cell membranes.  Also pictured are the two 
main steps that have been successfully targeted (coreceptor binding and viral fusion – approved 
therapeutics appear in parentheses) along with the primary target of most genetic therapies 
aimed at preventing HIV entry (in red). There are no approved therapies in this latter group. 
Adapted from Antiviral Research Vol 85, Tilton J.C. and Doms R.W, “Entry inhibitors in the 
treatment of HIV-1 infection,” 91-100, Copyright 2009, with permission from Elsevier. 
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Figure 3 – Simultaneous ZFN modification of ccr5 and cxcr4 protects SupT1-R5 T cells from 
infection with viruses that use either CCR5 or CXCR4. (A) Surface expression of CCR5 (R5) and CXCR4 
(X4) on SupT1-R5 cells following delivery of increasing multiplicity of infections (MOI) of the Ad R5- and X4-
ZFNs. Percent of cells lacking both coreceptors is labeled in red. (B) Proportion of cells lacking both surface 
R5 and X4 (double negative cells) following simultaneous treatment with the R5 (MOI 600) and X4 (MOI 
600) ZFNs as measured by FACS. (C) Dual ZFN treated cells were challenged with a mix of R5- and X4-
using HIV and surface expression of R5 and X4 was measured over time in infected and uninfected R5/X4-
ZFN treated cells. (D) The proportion of double negative cells following R5/X4-ZFN treatment and 
subsequent HIV infection was measured by FACS five and 25 days post-infection. (E) Cell viability after 
infection of mock (no ZFN) or R5/X4-ZFN treated supT1-R5 cells with a mix of R5- and X4-HIV. Viability was 
measured by FACS following treatment with a viability dye). (F) Dual-ZFN treated supT1-R5 cells previously 
challenged with HIV and no longer expressing either coreceptor (black bars) as shown in panel C, were re-
challenged with either R5-HIV, X4-HIV or VSV-G-HIV pseudoviruses expressing GFP. HIV pseudovirus re-
challenge of previously HIV-selected double negative cells resulted in 170-fold and 92-fold decreases in 
infection by R5 and X4-HIV respectively, whereas VSV-G pseudovirus infection was decreased only ~1.7-
fold. All graphs represent the mean (± standard error of the mean (SEM)) of four independent ZFN 
treatments and four independent infection experiments; P-values calculated using student’s t-test. 
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Figure 4 –ZFNs simultaneously disrupt ccr5 and cxcr4 in primary human CD4+ T cells. (A) Dual ZFN 
treatment does not result in a significant growth defect as determined by live primary CD4+ T cell count 
following simultaneous delivery of increasing amounts of the R5 and X4-ZFNs. Data is from one of three 
independent experiments. (B) ccr5 and cxcr4 gene modification increases in a dose-dependent manner 
following R5/X4-ZFN treatment, as measured by the Cel1 assay 7-10 days post-ZFN treatment. Data is from 
one of three independent experiments. (C) Primary CD4+ T cells were sorted by CXCR4 expression into 
CXCR4 high and CXCR4 low populations (left) following simultaneous R5/X4-ZFN treatment.  Successful 
sorting was confirmed by repeat FACS (right panel). Arrows indicate gating strategy. (D) ccr5 and cxcr4 
gene disruption was measured by cel1 following R5/X4-ZFN treatment and subsequent sorting by FACS into 
CXCR4-high and low populations.  ccr5 disruption is similar in the X4 high and X4 low populations 
suggesting ccr5 and cxcr4 disruption are not occurring in mutually exclusive cells. Data is from one of three 
independent experiments. (E) CD4+ T cells treated with equal MOIs of the AdGFP or the R5- and X4-ZFNs 
were stained with the memory markers CCR7 and CD45RO. (Tcm; CD45RO+CCR7-) and effector memory 
T cells (Tem; CD45RO+CCR7-). (F) ccr5 and cxcr4 gene modification in Tcm and Tem subsets was similar 
suggesting that long-lived Tcm cells can be efficiently rendered HIV-resistant. Data shown is from one of 
three independent experiments.  
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Figure 5. Primary CD4+ T cells treated with the R5 and X4-ZFNs and challenged with HIV 
have a survival advantage in vitro. (A) Primary CD4+ T cells treated with GFP, the R5-ZFN, or 
two vectors encoding the R5 and X4-ZFNs were challenged with a mix of two HIV strains—the 
R5-using virus Bal, and the X4-using virus HxB2. Dual ZFN treatment conferred a significant 
survival advantage in vitro compared to both the GFP and R5-ZFN control. Live cells were 
counted every three to four days for 32 days. Arrows indicate the time points where cells were 
reactivated with anti-CD3/CD28 magnetic beads. Data is from one of three independent 
experiments. (B) T7E1 analysis of ccr5 (top panel) and cxcr4 (bottom panel) gene modification 
reveals that HIV challenge enriches for ccr5 and cxcr4 disrupted cells. Analysis was performed 0 
and 21 days post infection. Data is from one of three independent experiments. (C) The 
proportion of modified ccr5 and cxcr4 alleles in cells treated with both ZFNs increases 
approximately 2-fold in the presence or absence of HIV, as measured by the T7E1 assay. Data is 
shown as the mean ± SEM of three independent experiments. P-values calculated using 
student’s t-test. 
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Figure 6 – Dual R5- and X4-ZFN treatment confers protection in vivo. (A) Experimental timeline of the in 
vivo study is shown. (B) All three treatment groups were successfully engrafted as measured 21 days post-
infusion and three days prior to infection with a slight decrease in CD4+ T cell counts in ZFN groups 
compared to the GFP control. (C) Dual ZFN treatment preserves CD4+ T cells in the spleen compared to 
controls. Spleens were obtained from infected animals from all animals at the time of euthanasia. Human 
CD4+ T cells were defined as CD45+ CD3+ CD4+ CD8- T cells by FACS. (D) Dual ZFN treatment confers 
long-term protection against HIV as measured by preservation of peripheral blood CD4+ T cell counts. All 
uninfected animals and 1 infected animal in the R5/X4-ZFN treated group were euthanized 34 days post 
infection due xenogeneic graft-versus-host disease. Infected animals were followed for 55 days after 
infection. All statistical analyses were performed using a Mann-Whitney U test. Error bars indicate the mean 
± SEM. 
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Figure 7 –Cells lacking both ccr5 and cxcr4 following R5/X4-ZFN treatment have a survival 
advantage in vivo in the presence of HIV. 
(A) The frequency of human ccr5 and cxcr4-modified genes significantly increases in the R5/X4-
ZFN treatment group over the course of the in vivo infection. ccr5 and cxcr4 disruption are stable 
over time in the absence of HIV infection suggesting there is no significant adverse effect of dual 
ZFN treatment. We performed illumina deep sequencing of the R5 and X4-ZFN target sites and 
identified ZFN-induced mutations at these sites in 8/9 uninfected and 8/9 infected animals. We 
were unable to obtain sequence information from one infected animal due to limiting quantities of 
CD4+ T cells, and euthanized one uninfected animal following the development of GVHD, and 
this animal is thus excluded. (B) We stained whole blood from infected and uninfected animals in 
the R5/X4-ZFN treatment group 34 days post-infection with human antibodies to identify human 
CD4+ T cells and determine surface levels of R5 and X4. Both CCR5 and CXCR4 expression 
were significantly reduced on dual ZFN treated cells in the presence of HIV challenge suggesting 
that coreceptor negative cells have an in vivo survival advantage due to ZFN treatment. 
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A.  
 
 
 
 
 
 
 
Figure 8. Sequence and activity of CCR5 targeted designer nucleases (A) Sequence overlap 
between CCR5 ZFN binding sites (red boxes), CCR5 TALEN binding sites (Blue boxes), and 
CCR5 CRISPR gRNA binding site (green) (B) The CCR5 targeted nucleases area all active at 
their target loci. Gene modification (%NHEJ) is as noted, and samples are described in adjacent 
table.   
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A. 
 
 
B. 
R5X4 rearrangements 
CATACAGTCAGTATCAGCTCTGTGGGTGGTTGTGTTCCAGTTTCAG 
CATACAGTCAGTATCAAGTAGGGGGAAAAGTGGTTGTGTTCCAGTTTCAG 
CATACAGTCAGTATCAAGTAGGGGGAAAAGTGGTTGTGTTCCAGTTTCAG 
 
X4R5 rearrangements 
TTCTACCCCAATGAC-GGGTTTCTGGAAGAATTTCCAGACATTAAA 
TTCTACCCCAATGACTGACCCCCTTCTGGAAGAATTTCCAGACATTAAA 
TTCTACCCCAATGACTGGGCCTAATTCTGGAAGAATTTCCAGACATTAAA 
TATCTGTGACCGCCTTGCCTGC----------------TTCTGGAAGAATTTCCAGACATTAAA 
TTCTACCCCAATGACTGTTTCTGGCTTCTGGGGTTAGCATTCCCAGACATTAAA 
TTCTACCCCAATGACTGTTTCTGGCTTCAGGGGTTAGAATTTCCAGACATTAAA 
Figure 9. Reciprocal translocations between CCR5 and CXCR4 CRISPRs following 
simultaneous administration (A) Nested PCR using CCR5 and CXCR4 specific primers to 
identify reciprocal translocations following simultaneous delivery of CRISPRs targeting both loci. 
Expected band sizes are as noted (B) Confirmation of CCR5:CXCR4 translocations using sanger 
sequencing. Representative sequences are shown 
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Figure 10. Identification of VEGFA CRISPR/Cas nuclease-induced rearrangements using 
nested PCR (A) T7 Endonuclease assay to measure gene disruption following delivery of 
CRISPR/Cas nucleases targeting two loci (T2 and T3) in the VEGFA gene. %NHEJ is as 
indicated. (B) Nested PCR on genomic DNA from 293T cells identified rearrangements between 
CRISPR/Cas on- and off-target loci only in cells that received the nucleases. Expected band 
sizes are as shown  
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A. 
VEGFA.T2:FMN1 
ccggaggcggggtggagggggtcttttggaaatgcaaatctcc 
cccggcgcggggtggggggggtcttttggaaatgcaaatctgc 
gtggacgcggcggcgagggggtcttttggaaatgcaaatctgc 
ccggaggcggggtggagggggtcttttggaaatgcaaatctgc 
cggcggcggacagtggacg-56bp-gggggtcttttggaaatgcaaatctcc 
ccacctcctccccggc-75bp-gcggggtggagggggtcttttggaaatgcaaatctcc 
ccacctcctccccggc-75bp-gcggggtggagggggtcttttggaaatgcaaatctcc 
Gccgcgggcaggggccggagcccgc-25bp/20bp-tcatgtcacatattcctctgctc 
B. 
VEGFA.T2:PAX6 
caggggccggagcccgcgcccgg-16bp/33bp-ccaggaatattatttataaccagga 
caggggccggagcccg-23bp-ggcggggtggaggggcccctaggagcgccttggtggg 
caggggccggagcccg-23bp-ggcggggtggaggggcccctaggagcgccttggtggg 
ggacgcggcggcgag-46bp-gcggggtggaggggcccctaggagcgccttggtggg 
ggccggcggcgg-66bp-cggggtggaggggcccctaggagcgccttggtggg 
C. 
VEGFA.T3:MAX 
gtgtgggtgagtgagtgtgtgc--3bp-cactcactcgctctctcac 
gtgtgggtgagtgagtgt------7bp-cactcactcactcactcac  
gtgtgggtgagt-----------13bp-cactcactcactcactcac 
D. 
VEGFA.T3:COMMD10 
acgtgtgtgt------------27bp-cgtgaggacatttaagatcta 
acgtgtgtgtctgtgtgggtgagtgag--8bp-gacatttaagatcta 
tgtgggtgagtgagtgtgtgc-8bp-tttaagatcta 
tgtgtgggtgagtgagtgtgtg-3bp-gtgaggacatttaagatcta 
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Figure 11. Sanger sequencing reveals genomic rearrangements following treatment of 
293T cells with a single VEGFA-targeting CRISPR/Cas nuclease (A) Sanger sequencing 
results showing translocations between VEGFA.T2 and off-target site FMN1. (B) Sanger 
sequencing results showing translocations between VEGFA.T2 and off-target site PAX6. (C) 
Sanger sequencing results showing translocations between VEGFA.T3 and off-target site MAX. 
(D) Sanger sequencing results showing translocations between VEGFA.T3 and off-target site 
COMMD10. VEGFA sequences are in black and off-target site sequences are in blue. Deletions 
are indicated as number of base pairs and may involve either or both genes, and black 
nucleotides indicate mutations. 
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